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ABSTRACT
TEMPORAL EXPRESSION OF PROTEIN MEDIATORS DURING PGF2a- 
INDUCED LUTEOLYSIS IN SHEEP
By
Bryon Ricketts 
University of New Hampshire, Sept, 2006 
To study dynamic in vivo biochemical changes within the corpus luteum (CL) 
during luteolysis, a physiological model mimicking the onset of natural luteolysis was 
established, in which sheep received sequential systemic pulses of PGF2a (20ug/min/lhr) 
at mid-luteal phase of the estrous cycle. We previously demonstrated that after one pulse 
of PGF2a, the protein levels of extracellular matrix (ECM) regulators, tissue inhibitors of 
metalloproteinases (TIMPs) -1 and -2 decreased dramatically within one hour of PGF2a 
infusion, while matrix metalloproteinase (MMP)-2 activity increased 4 hrs post infusion. 
Protein levels of steroidogenic acute regulatory (StAR) protein decreased (40%) at 8 hrs, 
which paralleled the decline in peripheral plasma progesterone (P), before recovering by 
16 and 24 hrs. COX-1 was unchanged, while COX-2 displayed a dramatic increase 
(~300%) at 16 and 24 hrs compared to all other time points. In the present study, we 
examined the protein expression patterns of TIMP-1, TIMP-2, MMP-2, MMP-9, COX-1, 
COX-2, and StAR following two systemic pulses of PGF2a (20ug/min/lhr) given 16 hrs 
apart at mid-luteal phase. Corpora lutea were removed surgically 1 hr before and 1, 8, 
16, and 24 hrs after the second pulse of PGF2a (n=4 sheep/time point). Peripheral blood
vm
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for monitoring plasma progesterone (P) was collected hourly before and after each pulse 
of PGF2a. The TIMP-1 protein showed a sharp decline (-50%; p<0.05) one hour post­
infusion before returning to control values by 8 hrs and continuing to rise above control 
levels by 24 hrs (30%; p<0.05). The TIMP-2 protein also declined sharply 1 hr and 
remained low throughout the sampling period. Active MMP-2 increased 1 hr following 
infusion (-20%; p<0.05), while COX-1, and COX-2, and StAR protein levels showed no 
change compared to controls. In summary, the early and dramatic decrease in TIMP-1 
and TIMP-2 proteins, accompanied by an increase in MMP-2 activity, indicate an 
extension and amplification by the second pulse of PGF2a on regulators of the ECM 
within the CL. These findings confirm a critical role for regulators of the ECM in 
mediating both structural and steroidogenic changes during physiological PGF2a-induced 
luteolysis in sheep.
IX
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CHAPTERI
TEMPORAL EXPRESSION OF PROTEIN MEDIATORS DURING PGF2a-
INDUCED LUTEOLYSIS IN SHEEP: A LITERATURE REVIEW
Introduction
The goal of all organisms is to pass their genetic information to subsequent 
generations. To accomplish this, mammals reproduce sexually. It can be said that all 
facets of an organism’s life, ranging from growth, development, nutritional health, 
and physiological functions, can be attributed to facilitating reproduction. The ability 
of mammals to reproduce is dependent on several key features of sexual reproduction. 
There must be a component contributed by a male, the sperm, and from the female, 
the ovum. The research that is covered under the present review is limited to female 
reproduction, specifically the ovarian follicle and a gland called the corpus luteum 
(CL), whose functions are essential for pregnancy. It has been reported and widely 
accepted that both of these reproductive structures, the follicle and CL, are influenced 
by eicosanoid hormones, the prostaglandins (PGs) (Espey 1980; McCracken et al. 
1981).
Since the focus of this review is mainly on the role of PGs in luteolysis, it is 
important to first introduce the background information on the sheep reproductive 
cycle to provide context for the sequence of events that culminate with the process of 
luteolysis, or the structural and functional demise of the CL. Mammals display an 
estrous cycle, excluding primates. Sheep and cows display a poly cyclic estrous cycle, 
which means that if pregnancy does not occur after ovulation, luteolysis occurs to
1
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allow a new cycle to start. However, sometimes there are periods of anestrous, or 
times when there are breaks in the cycle (e.g. sheep) (Garverick and Smith 1993). 
The estrous cycle is broken into two dominant phases, the follicular phase and the 
luteal phase. The follicular phase encompasses the growth and development of the 
follicle and culminates with ovulation, and is characterized by the predominance of 
the hormone estradiol. The luteal phase entails the luteinization, maturation, and 
regression of the CL, and this period is characterized by progesterone production 
(Niswender et al. 1994). The estrous cycle as a whole is controlled by various 
components of the reproductive system, ranging from the hypothalamus to the 
anterior pituitary to the reproductive tract. The reproductive tract is composed of the 
ovary and duct system, spanning from the external genitalia, vagina, cervix, uterus, 
and oviducts to the ovary.
To understand how the estrous cycle is controlled by the reproductive system 
it is important to grasp the structural makeup of the reproductive tract. The two 
separate, highly vascularized, bipartite uterine horns of the ewe and cow are 
composed of three tissue layers. The outermost layer is called the myometrium and 
consists of a longitudinal muscle layer between two circular layers of muscle. The 
middle layer is called the endometrium. This layer is composed of glandular tissue 
that builds and regresses over the course of an estrous cycle (Niswender and Nett 
1994). The endometrium is the layer that the fetus implants if fertilization does 
occur. And finally, the innermost layer is the epithelium, which lines the lumen of 
the uterus.
2
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The duct system continues to the two ovaries, the site of most interest for this 
study. The ovary is a very dynamic organ that is constantly undergoing stages of 
remodeling. The ovary is composed of a central medulla that contains the nerve, 
blood, and lymph supply (Espey and Lipner 1994). The next layer is the peripheral 
cortex, which contains the developing ova in follicles until maturation and subsequent 
ovulation. The tunica albuginea, a thin layer of dense connective tissue surrounds the 
peripheral cortex and basement membranes. The serous/germinal epithelium sits atop 
the tunica albuginea which is periodically broken to permit the release of the oocyte 
during ovulation (Espey and Lipner 1994).
Prostaglandins regulate a variety of proteins that mediate events associated 
with follicular development, ovulation, luteotropism, and luteolysis. In the present 
study, the focus is on how PGF2a influences various protein mediators during the 
process of luteolysis. These mediators include matrix metalloproteinases (MMPs), 
which are enzymes responsible for degrading the extracellular matrix (ECM), and 
their endogenous inhibitors, the inhibitors of metalloproteinases (TIMPs). The 
balance between MMPs and TIMPs influences the rate of proteolysis and the type of 
ECM degradation that occurs, which are thought to ultimately lead to structural 
regression of the CL. Another mediator of interest is the steroidogenic acute 
regulatory protein (StAR). StAR is responsible for cholesterol transport allowing for 
steroid synthesis, thus providing insight into the functional aspects of the corpus 
luteum. Also important in this study are the cyclooxygenase (COX) enzymes. COX 
enzymes regulate the synthesis of PGs, fueling the auto-amplification of luteolysis
3
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through PG production within the CL. Therefore, the present literature review is 
intended to discuss the aspects of ovarian function that relate PGF2a and luteolysis.
Prostaglandins
Collectively eicosanoids encompass an entire group of compounds that 
include PGs, thromboxanes (TXs), leukotrienes, lipoxins (LPXs), and 
hydroxyeicosanoic acids (HETEs) (McCracken 2005). Prostaglandins are hormones 
derived from the essential 20 carbon fatty acids. The predominant 20 carbon 
precursor is arachidonic acid (AA) (Poyser 1973). AA is readily liberated from 
membrane phospholipids, which are found in all cell membranes. Prostaglandins are 
very biologically active and are metabolized readily by most tissues in the body, 
particularly the lung (Samuelsson 1964). As a result of their rapid metabolism, 
prostaglandins are synthesized in many tissues to serve in a variety of biological 
processes, particularly at sites of inflammation. For the purpose of the present 
review, I will focus mainly on PGs, particularly PGF2a.
Prostaglandin (PG) Biosynthesis
PG synthesis begins with the liberation of AA from plasma membrane 
phospholipids by two phospholipases, A2 and C. These enzymes are responsible for 
providing AA, the preferred precursor to the 3-step cyclooxygenase pathway that 
leads to PG synthesis (Kunze and Vogt 1971; Lands and Samuelsson 1968). There 
are three forms of the PG endoperoxide H synthases responsible for AA metabolism: 
cyclooxygenase 1 (COX-1), which is the constitutively expressed isoform;
4
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cyclooxygenase 2 (COX-2), which is the induced isoform; and cyclooxygenase 3 
(COX-3), a relatively new isoform with little known function. These COX enzymes 
convert AA into prostaglandin G2  (PGG2) and subsequently to prostaglandin H2  
(PGH2) (Vane and Botting 1995). PGH2 then undergoes an isomerization by 
prostaglandin F synthase to yield the product PGF2a (Smith et al. 1996).
Cyclooxygenase Enzyme Function
Cyclooxygenase (COX) enzymes are membrane bound enzymes (Smith and 
Dewitt 1996) capable of both peroxidase and cyclooxygenase activities (Smith et al. 
1996). The cyclooxygenase activity enables the addition of two oxygen molecules to 
AA through an oxidation reaction to produce PGG2 , and the peroxidase activity 
follows, which adds two electrons through a reduction reaction to produce PGH2 
(Smith and Dewitt 1996; Smith et al. 1996). Figure 1 depicts how PGH2  is converted 
into a number of PGs and related products by their specific synthases.
5
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Adapted from (McCracken 2005).
There are two well known and highly documented isoforms of the COX 
enzyme, COX-1 and COX-2 (Herschman 1994). Recently a third isoform was 
identified. While this isoform is not very well characterized, it is localized 
predominantly in the brain (Botting 2000; Hersh et al. 2005). Therefore, I will focus 
on COX-1 and COX-2 and their relevance to ovarian function. Both COX-1 and 
COX-2 cDNA share up to 60% amino acid sequence homology (Vane et al. 1998). 
This homology extends beyond the bounds of evolution, and can remain up to 90% 
homologous between species (Kulkami et al. 2000). Table 1 depicts some of the 
general and distinguishing characteristics of COX-1 and COX-2.
6
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Table 1. Comparisons of COX-1 and COX-2 Characteristics
Physiology • constitutive form
• produces PGs that regulate 
normal kidney, stomach 
function and vasculature 
homeostasis
• inducible form
• induced during periods of 
inflammation, produces 
PGs involved in the 
inflammatory response; 
may have roles in 
regulating mitogenesis and 
cell growth
Amino Acids • 599 aa • 604 aa
Molecular
Weight




• gene is 22 Kb, 11 exons
• gene is located on 
chromosome 9
• mRNA transcript is 2.8 to 
3.0 Kb
• mRNA transcript is not 
degraded quickly
• promoter gene has low 
inducibility
• not inhibited by 
glucocorticoids
• gene is 8.3 Kb, 10 exons
• gene is located on 
chromosome 10
• mRNA transcript is 4.0 to 
4.5 Kb
• mRNA transcript is 
degraded quickly
• promoter region contains 
many transcriptional 
factors which can be 
upregulated by 
proinflammatory cytokines




• chronic inflammation 
phase
• acute inflammation phase
Adapted from (Kulkami et al. 2000).
The COX enzymes are integral membrane proteins that undergo post- 
translational modifications (e.g. glycosylation and homodimerization), however, the 
COX enzymes are slightly different in size and in the composition of their active sites 
(Kulkami et al. 2000; Luong et al. 1996). As mentioned in Table 1, the COX 
enzymes differ in length by 5 amino acids. COX-1 is 599 amino acids and has a 
relative molecular mass of -70 kDa, while COX-2 is 604 amino acids and has a 
relative molecular mass of -72 kDa (Kulkami et al. 2000). COX-1 is constitutively
7
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expressed and is responsible for regulating renal water and sodium metabolism, 
stomach acid, and vascular homeostasis (Smith and Dewitt 1996; Smith et al. 1996; 
Vane et al. 1998). COX-2 is the inducible form of the gene and is upregulated in the 
early inflammation response. Upregulation of COX-2 is initiated by factors such as 
growth factors and cytokines during times of acute inflammatory responses, as seen 
in disease states (e.g. arthritis, colon cancer, and Alzheimer’s diease) (Vane et al. 
1998) and also during ovulation and luteolysis (Espey 1980; McCracken et al. 1972).
COX structure
COX was first purified in 1976 (Hemler and Lands 1976; Miyamoto et al. 
1976), and first cloned in 1988 (DeWitt and Smith 1988; Merlie et al. 1988). In 1994, 
X-ray crystallography revealed the structure of ovine COX-1 (Picot et al. 1994), as 
depicted in Figure 2. The three-dimensional structure of the integral membrane 
protein, COX-1, is a bifunctional enzyme comprised of three independent folding 
units: an epidermal growth factor domain (EGF), a membrane-binding motif (MBD) 
and an enzymatic domain. Two adjacent active sites were found for its heme- 
dependent peroxidase and cyclooxygenase activities (Picot et al. 1994). The 
cyclooxygenase active site is created by a hydrophobic channel that is the site of non­
steroidal anti-inflammatory drug binding (aspirin or COX inhibitors) (Vane and 
Botting 1995). The conformation of the membrane-binding motif suggests that the 
enzyme integrates into only one leaflet of the lipid bilayer and is thus a monotopic 
membrane protein (Picot and Garavito 1994).
8
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Adapted from (Smith and Dewitt 1996)
The EGF domain ranges from residue 34 to 72, contains two P-sheets and 
three intra-domain disulfide bonds. The disulfide bond that connects cysteines 37 to 
159 is responsible for attaching the EGF domain to the enzymatic domain, or active 
site (Picot et al. 1994).
The MBD is composed of four a-helices and ranges from residues 73-116; 
this is the portion of the protein that inserts into the organelle membranes (Picot and 
Garavito 1994; Picot et al. 1994). Some organelles, in particular, are the endoplasmic 
reticulum (ER) and the nuclear envelope (NE). Immunocytofluorescence reveals that 
COX-1 is localized in lipid bodies as well as the ER and NE of murine 3T3 cells, and 
human (HUVEC) and bovine (BAEC) endothelial cells (Dvorak et al. 1994). COX-2 
is predominantly localized in the NE over the ER, and has been seen within the 
nucleus (Vane et al. 1998). Although the patterns of localization of COX-1 and 
COX-2 are somewhat similar, it is believed that COX-1 is active primarily in the ER 
while COX-2 is active in the NE as well as the ER (Morita et al. 1995).
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As mentioned above the MBD region contains four a-helices. This is 
important because the fourth a-helix is associated with the heme-dependent active site 
of the enzyme (Vane et al. 1998). This active site facilitates both cyclooxygenase and 
peroxidase reactions (Luong et al. 1996; Picot et al. 1994). These reactions take place 
in a hydrophobic channel in the COX enzyme that is stereochemically 
accommodating for membrane associated AA. The a-helices compose this 
hydrophobic channel that allows COX to interact with AA within a lipid bilayer 
(Picot et al. 1994). The C-terminus of the protein contains an ER targeting and 
retention signal (Pro-Thr-Glu-Leu) (Smith and Dewitt 1996; Smith et al. 1996). 
Although the COX-1 and COX-2 amino acid structures are highly conserved 
evolutionarily (Luong et al. 1996), there are some major differences in their 
regulation and expression.
COX Regulation
The differences in COX-1 and COX-2 transcripts lie on different genes (Smith 
and Dewitt 1996; Smith et al. 1996). The 3’ untranslated region of COX-2 contains 
several Shaw-Kamen sequences, which are amino acid sequences commonly 
associated with mRNA degradation (Jouzeau et al. 1997). These 18 amino acid 
inserts may account for the relatively short half-life of COX-2 mRNA and protein 
(Smith et al. 1996).
Recent research has shown that protein kinase C (PKC) directly regulates 
COX-2 transcription in large luteal cells (LLCs) through several upstream leucine 
zipper transcription factors (Wu and Wiltbank 2001a; Wu and Wiltbank 2001c).
10
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These upstream transcription factors bind to an E-box (-CACGTG-) that lies only 50 
base pairs upstream from the COX-2 transcript (Wu and Wiltbank 2001c). In 
addition, when LLCs are treated in vitro (Tsai and Wiltbank 1997) and in vivo (Wu 
and Wiltbank 2001a) with a protein kinase C activator, ionomycin (calcium 
ionophore), COX-2 mRNA concentrations increase significantly.
There is debate over the belief that nitric oxide (NO) influences COX 
expression and is a primary regulator of COX activity. Binding kinetics show NO to 
be a weak ligand for COX-1, leading researchers to believe that no direct interactions 
exist between NO and COX-1 expression, at least at physiological concentrations 
(Tsai and Wiltbank 1997). Although COX-1 does not seem to be a primary target of 
NO, evidence suggests that endogenous NO or endogenous NO donors may be a 
regulator of COX-2 activity (Mollace et al. 2005; Salvemini et al. 1994). It is 
probable that there are many regulators of COX expression, however, many of them 
have yet to be characterized.
COX Expression
As mentioned previously COX-1 is constitutively expressed, whereas COX-2 
is inducible. In sheep, COX-1 is expressed constitutively throughout the estrous 
cycle and pregnancy mainly in the myometrium of the uterus, whereas COX-2 is 
expressed mainly in the endometrium and is expressed in the highest concentrations 
on days 12-15 of the estrous cycle (Charpigny et al. 1997). Results of in vitro 
experiments show that COX-2 mRNA expression increases within 4 hours after ovine 
luteal cells are treated with 100 nM PGF2a (Tsai and Wiltbank 1997; Tsai and
11
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Wiltbank 2001), and remains high for up to 12 hours following treatment. Tsai and 
Wiltbank also demonstrated that LLCs contain 1000 times more COX-2 mRNA 
transcripts than small luteal cells (SLCs). These studies propose a positive feedback 
loop for PGF2a upregulating intraluteal COX expression, which suggests that COX-2 
may play an integral role in luteolysis. These findings, coupled with those that 
indicate NO may regulate COX expression, suggest a possible synergistic relationship 
between PGF2a, NO, COX during luteolysis.
PGF2a Mechanism of Action
PGF2a receptors belong to the family of 7-transmembrane heterotrimeric G 
protein-coupled receptors (Abramovitz et al. 1994; Anderson et al. 2001). Binding of 
PGF2a leads to activation of the PGF2a receptor via phosphorylation. Receptor 
activation induces a cascade of events leading to the activation of various cellular 
components including phospholipase C (PLC). PLC is a membrane bound enzyme 
responsible for catalyzing the formation of inositol 1,4,5-triphosphate (IP3) and 1,2- 
diacylglycerol (Bourdage et al. 1984) lfom the membrane component 
phosphatidylinositol (PI). IP3 initiates a release of intracellular Ca++ from the smooth 
ER (Berridge and Irvine 1984; Davis et al. 1988) and also opens calcium channels on 
the plasma membrane causing an influx of extracellular Ca++ (Kuno and Gardner 
1987). These effects are thought to be limited to LLCs, and not SLCs (Alila et al. 
1989). DAG acts in concert with excess Ca++ activate another membrane bound, 
calcium-dependent enzyme called protein kinase C (PKC) (Niswender et al. 2000).
12
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The activation of PKC through binding of PGF2a to its receptor leads to an 
acute inhibition of progesterone synthesis 8 hours following treatment (Beal et al. 
1980; Wiltbank et al. 1991). This pathway is believed to affect LLCs through 
decreasing cholesterol availability (Behrman et al. 1971) and ECM stability, and even 
apoptosis (Niswender et al. 2000). PKC has been linked to the stimulation of PGF2a 
production via an auto-amplification feedback loop (Shemesh et al. 1989; Wiltbank 
and Ottobre 2003), PKC affects gene expression and/or the modification of various 
cellular proteins that play a role in PGF2a production (e.g. COX 
enzymes/PLA2)(Shemesh et al. 1989). PKC’s effects are not limited to PGF2a 
production. Examples of genes/proteins affected by PKC are steroidogenic acute 
regulatory protein (StAR), which is responsible for progesterone production (Manna 
and Stocco 2005), and ECM mediators such as tissue inhibitors of metalloproteinases 
(TIMPs) and matrix metalloproteinases (MMPs) (Smith et al. 1997).
Follicular Development
The follicular phase describes the growth and development of ovarian 
follicles. This is a process that is continuous throughout the estrous cycle, but most 
developing follicles never reach full matu23rity. Most follicles (99.9%) that are 
selected and recruited for development regress through a natural process called atresia 
(Fortune et al. 1991; Peters et al. 1975; Quirk et al. 1986). For many years the 
development of the follicle has been reported to be influenced by PGs. The PGs are 
produced by follicular tissues in considerable quantities throughout development 
(Erickson et al. 1977; Triebwasser et al. 1978), due to PG synthesis stimulated by
13
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gonadotropins (Evans et al. 1983). This is predominantly characterized by the steroid 
hormone, 17p-estradiol (E2), which is being produced at higher quantities than the 
rest of the cycle. The developing follicles are producing E to bathe the maturing 
oocytes, eventually leading to a surge of LH and eventual ovulation (Fortune 1994; 
Fortune and Armstrong 1978). Before delving into the follicle’s role in 
steroidogenesis, it would be pertinent to first review follicular structure and function.
Follicle Development and Structure
The multiplication of oogonia (primordial germ cells) and the development of 
primordial follicles occurs during embryonic development in female mammals 
(Peters et al. 1975). It was believed that by the time gestation is complete, the ovary 
will contain the most oocytes that it will ever possess, and from this point on, the 
number of oocytes will decrease through the above mentioned process of atresia. 
However, there is now evidence that mammals possess the ability to produce germ 
cells and follicular renewal postnatally (Bukovsky et al. 2004; Johnson et al. 2004). 
Although several follicles are recruited each cycle, most will never reach maturity 
and ovulate (Quirk et al. 1986).
Follicles have various stages of development according to their morphological 
characteristics. The first stage of development begins with primordial follicles, which 
describes the immature oocyte being surrounded by a single layer of squamous 
(pregranulosa) follicle cells (Baca and Zamboni 1967; Sirois and Fortune 1988). 
Primordial follicles then develop into primary follicles with the addition of a 
basement membrane surrounded by a single layer of cuboidal cells (Bjersing 1982;
14
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Fortune et al. 2000; Stegner et al. 1976). If the follicle is still being recruited, it then 
develops into a secondary follicle, which is characterized by the addition of a thick 
translucent layer around the oocyte, called the zona pellucida, and is accompanied by 
the growth of multilaminar granulosa cells that are 2-6 layers thick (Bjersing 1982). 
As development continues, the number of theca and granulosa cells increases, which 
leads to the formation of a tertiary, or antral follicle due to the accumulating fluid in 
the antrum. This follicular fluid contains various proteins, carbohydrates, steroids, 
and polysaccharides that bathe the developing ovum through maturation (McNatty 
1978; McNatty and Baird 1978). The final stage of follicular development is 
characterized by a decrease in systemic progesterone (P) concentrations, due to the 
regression of the CL from the previous estrous cycle, and an increase in estradiol (E2) 
concentration which is secreted by developing follicles (McNatty et al. 1979). This 
last stage is when the follicle is referred to as a dominant, or Graffian follicle.
Follicular Function
Follicular function is characterized by the development of the theca layer, and 
subsequent production of E (McNatty et al. 1984; McNatty et al. 1979). Both 
granulosa and theca cells are involved in the process of steroid production, but for 
most species, each is incapable of metabolizing cholesterol into 17(3-estradiol due to 
lack of appropriate enzymes. The cooperation of the granulosa and theca cells in 
steroid production is described as the “two-cell theory” (Falck and Hillarp 1959; 
Short 1962). The complete conversion of cholesterol > progestogens > androgens >
15
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
estrogens (Payne and Hales 2004) possible is only through a combination of enzymes 
found in both the granulosa and theca cells.
Steroid production begins in the theca interna cells with their ability to 
produce and secrete androgens in response to an LH stimulus (McNatty et al. 1979). 
The theca interna cells possess a large concentration of 17a-hydroxylase activity 
required for androgen synthesis, however, they lack enzymes required to metabolize 
androgens any further (Bjersing 1968). Instead, thecal androgens (androstenedione 
and testosterone) cross the basement membrane to the granulosa cells, where they are 
converted to estradiol by the aromatase enzymes (Fortune and Armstrong 1978). 
Aromatase activity increases in granulosa cells in response to follicle stimulating 
hormone (FSH), and thus increasing E producion (Fortune and Hilbert 1986). As 
follicular development continues, there is an increase of E concentration in the 
follicular fluid, which increases granulosa cell sensitivity to FSH and luteinizing 
hormone (LH) (Richards et al. 1987). Estradiol also crosses the basement membrane 
where it is transported through the blood stream to various target tissues, including 
the brain.
Endocrine Regulation of Follicle Development
The hypothalamus and the anterior pituitary play a large role in regulating the 
growth and development of follicles. There are two groupings of nerve bodies, called 
nuclei, which are involved in regulating the estrous cycle. These nuclei are known as 
the tonic center (ventromedial and arcuate nucleus) and the surge center (preoptic and
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suprachiasmatic nuclei, and anterior hypothalamus). Both of these brain centers are 
responsible for producing the decapeptide, gonadatropin releasing hormone (GnRH). 
GnRH is released from the nerve endings of these nuclei and into the capillary 
network called the hypothalamo-hypophyseal portal system (Niswender and Nett 
1994). It arrives at the anterior pituitary where it stimulates the release of FSH and 
LH in a pulsatile manner (Garverick and Smith 1993; Turzillo et al. 1995). Since 
1940, it has been accepted that both FSH and LH are required for follicular 
development (Fevold 1941), which are required for stimulating E production 
(Goodman et al. 1981).
In ruminants, tonic GnRH secretions are responsible for the waves of 
follicular growth that result mainly in atresia, or death of follicles (Noel et al. 1993). 
As follicular development continues, small quantities of a glycoprotein hormone 
called inhibin are produced. Inhibin is responsible for inhibiting the release of FSH 
(Ying 1988), which prevents the further recruitment of follicles, but leaves secondary 
and tertiary follicles unaffected. At this time, it appears that the follicles switch from 
their dependency on FSH to LH, as seen by a decrease in FSH receptors and an 
increase in LH receptors on granulosa cells (Carson et al. 1979; Niswender et al. 
1985a).
Under conditions of low progesterone, E feedback reaches a threshold causing 
the pulse generator in the hypothalamus to increase in amplitude and frequency 
(Baird and McNeilly 1981). The surge center of the pituitary responds with a release 
of LH, which ultimately causes ovulation.
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PGs in Ovulation
The growth and maturation of the follicle is designed for the single purpose of 
ovulation. Ovulation is the event that releases the oocyte to the Fallopian tubes in an 
attempt to facilitate the process of fertilization and subsequent pregnancy. Ovulation 
has been compared to an inflammatory response involving various hormones and 
proteins, but most importantly PGs (Espey 1980). The process begins with 
luteinizing hormone (LH), which is responsible for initiating the cascade of events 
culminating in ovulation (Niswender et al. 1986). Some of the many components 
affected by this LH surge are the morphology, biochemical, and endocrine function of 
the follicle cells. PGs are thought to contribute to this inflammatory process through 
their capacity to intensify vascular leakage induced by mediators such as histamine 
and bradykinin (Vane 1976). In concert with the effects on the vasculature, PGs 
facilitate the destruction and remodeling of connective tissue elements (Espey 1980) 
by induction of proteolytic enzymes, thus pushing the inflammation to the chronic 
stages, eventually leading to ovulation.
Several mechanisms may explain in part how PGs, particularly PGF2a, 
generate large amounts of PGF2a, in an auto-amplification manner, to propagate the 
inflammatory nature of this process. PGs are leukotactic, in that once leukocytes 
arrive at the site of inflammation, they release additional PGs into the area of 
inflammation (Lewis 1977). Another mechanism of action involves the PKC 
pathway discussed earlier. Since PGs act through a pathway that involves PKC, PKC 
may directly target genes/enzymes that are involved in PG synthesis, thus up-
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regulating their expression/activation leading to increased production of PGs (Tsai 
and Wiltbank 1997; Wiltbank and Ottobre 2003).
Luteinization
Once ovulation has occurred, the cells that comprised the follicle undergo a 
process known as luteinization. This process is regulated, in part, by prostaglandin E 
(PGE) and PGF2a, which act in conjunction to promote luteinization of granulosa and 
theca cells, and subsequent stimulation of P synthesis (McArdle 1990). Luteinization 
is caused by the preovulatory surge of LH, and it involves the transformation of theca 
and granulosa cells into luteal cells, leading to drastic increases in P production 
(Pescador et al. 1999; Smith et al. 1994b). Luteinizing hormone is the luteotrophic 
hormone in both sheep (McCracken et al. 1971) and cows (Hansel and Seifart 1967). 
The follicular fluid contains LH inhibitors, thus preventing luteinization until after 
ovulation. These two inhibitors are inhibin and LH receptor binding inhibitor 
(LHRBI) (Channing et al. 1980). Once the follicular fluid containing the inhibitors is 
gone, LH is capable of binding its receptors which causes an increase in adenosine 
3’,5’-monophosphate (Dimino et al. 1976; Niswender and Nett 1994). The increase 
in cAMP levels causes cells to acquire cytoplasmic projections, along with large 
numbers of smooth endoplasmic reticulum and mitochondria, and most importantly, 
the ability to produce and secrete progesterone (Niswender and Nett 1994). With 
these acquired characteristics, granulosa and theca cells transform into luteal cells. 
Simultaneous with the transformation of luteal cells, the developing corpus luteum 
undergoes a stage of extensive vascularization, or angiogenesis, as endothelial cells
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invade the avascular granulosa compartment (Smith et al. 1994b), making the corpus 
luteum one of the most vascularized tissues in the body (Ford et al. 1982).
Corpus Luteum (CL)
The corpus luteum (CL) is a transient endocrine gland (Loeb 1923b) that 
forms from the follicle, the structure that houses the ovum. The CL is responsible for 
producing P, the steroid hormone that allows for implantation and maintenance of the 
fetus. The CL is essential for maintenance of pregnancy until the placenta develops 
and takes over P production, thus allowing the fetus to survive until parturition. 
Ultimately, proper functioning of the CL is essential for mammals to pass on their 
genetic characteristics through reproduction.
Structure of the CL
The structure of the CL is comprised of a variety of cell types including 
fibroblasts, endothelial cells, macrophages, and steroidogenic luteal cells (Farin et al. 
1986). All of these cell types act in concert to regulate vascularization, and luteal cell 
function, particularly steroidogenesis (Devoto et al. 2002). For the present 
discussion, I am going to focus only on the steroidogenic luteal cells of the CL.
There are two functionally distinct types of steroidogenic luteal cells present 
in the CL, large luteal cells (LLCs), and small luteal cells (SLCs) (Rodgers et al. 
1986; Ursely and Leymarie 1979). It is generally accepted that LLCs develop from 
granulosa and SLCs develop from theca cells during the process of luteinization 
(Alila and Hansel 1984; Farin et al. 1986). These cell populations are distinguishable
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based on cell diameter, with cells <22 pm being SLCs and >26 pm being LLCs 
(O'Shea et al. 1989; Rodgers et al. 1986). Both theca and granulosa cells acquire the 
morphological and functional characteristics of small and large luteal cells 
respectively in vitro (Meidan et al. 1990). During the process of luteinization, LLCs 
develop increased numbers of ER and mitochondria, both of which are essential for 
biosynthesis of steroids (Murphy 2000; Niswender et al. 2000; Niswender and Nett
1994). Morphologically LLCs have a polyhedral shape with a centrally located 
nucleus and distinct nucleoli, and large numbers of mitochondria surrounding the 
nucleus. Conversely, SLCs have an angular-spindle shape with a cup-shaped nucleus 
and irregular shaped nuclei, and an accumulation of lipid droplets within their 
cytoplasm (Niswender et al. 1994).
Both LLCs and SLCs comprise between 30% (O'Shea et al. 1989) to 36% 
(Farin et al. 1986; O'Shea 1987) of the cell population in the mid-cycle CL. These 
cell populations are found in a ratio of 6:1 of SLC:LLC (O'Shea et al. 1989) with 
LLCs comprising 4% of the total cell population and 25% of the CL total volume, and 
SLCs comprising 19% of the cell population and 18% of the CL total volume (Farin 
et al. 1986; McCracken et al. 1999; O'Shea et al. 1989). However, these estimates 
may be influenced by the age of the CL. LLCs exit the cell cycle upon luteinization, 
thus rendering them incapable of replication, however, SLCs are thought to replicate 
as much as 5-times between days 4-16 of the ovine estrous cycle (Farin et al. 1986; 
Niswender et al. 2000).
The CL is one of the few adult tissues that undergoes regular periods of 
growth, development, and regression (Jablonka-Shariff et al. 1993). The growth and
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development of the CL is very rapid. Following ovulation, the sheep CL weighs 
about 30-40 mg, and by day 12 of the ovine estrous cycle the CL can weigh as much 
as 750 mg, a 20-fold increase in tissue mass after only 12 days. At this rate, the 
doubling time for luteal tissue mass is about 60-70 hours (Reynolds et al. 1994). 
During this time it is essential that the tissue undergoes a time of rapid vascularization 
to maintain nutrient supply and waste removal. The endothelial cells present in the 
CL, which make up 30-40% of cell population (Devoto et al. 2002), help to facilitate 
this period of angiogenesis (Grazul-Bilska et al. 1997; Jablonka-Shariff et al. 1997). 
This rate of tissue growth is comparable to that of tumor growth (Reynolds et al.
1994), suggesting that there is, to an extent, an amount of flexibility within the CL to 
allow for rapid growth and expansion of the tissue (Redmer et al. 1988).
Function of the CL
The main purpose of the CL is the production of P, a steroid hormone that 
facilitates pregnancy through the preparation of uterine tissue, thus allowing embryo 
implantation (Charming et al. 1980; Moeljono et al. 1977; Niswender et al. 1994). 
After implantation of the fertilized ovum into the uterine wall, P production is still 
required by the CL until the fetal placenta matures enough to produce P on its own 
(Casida LE 1945). In fact, the CL remains functional throughout most of pregnancy 
(Hansel and Seifart 1967; Silvia and Niswender 1984).
The regulation of progesterone production differs between LLCs and SLCs. 
When both LLCs and SLCs are separated and treated in vitro with LH, LLC 
production of P is unaffected by LH, whereas SLC production of P increases by as
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much as 20 times (Fitz et al. 1982). This indicates that LH stimulates P production by 
SLCs, but not LLCs. However, LLCs are the main source of P in the CL by 
producing 80% of the circulating P levels (O'Shea 1987).
Progesterone Biosynthesis
As mentioned above, the majority of luteal P is produced by LLCs (80%), 
nearly 20 times the amount synthesized by SLCs (Niswender et al. 1985b). LH 
stimulates P synthesis in SLCs by regulating genes necessary for P synthesis (Devoto 
et al. 2001). The upregulation of the steroid biosynthesis machinery leads to a 40- 
fold increase in P production from SLCs (Fitz et al. 1982) due to the fact that SLCs 
have over 10 times the number of LH receptors compared to LLCs (Glass et al. 
1984). LLCs rate of P synthesis is not affected by LH. However, when over- 
stimulated by LH, SLCs have the ability to down-regulate LH receptors, suggesting 
that there is a defined biological regulation of P biosynthesis (Niswender and Nett
1994). As the young CL matures, serum concentrations of P can increase by as much 
as 25 times.
LH regulates P synthesis by affecting several key mediators. LH binds to a 
heterotrimeric G-coupled protein that leads to the activation of adenylate cyclase 
(Davis et al. 1989). This leads to an increase in cAMP concentrations, and 
subsequent activation of protein kinase A (PKA). PKA phosphorylates cellular 
proteins to elicit various biological responses such as gene transcription, protein 
synthesis, and protein activation (Niswender and Nett 1994).
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One protein that is affected by PKA, in particular, is steroidogenic acute 
regulatory protein (StAR). PKA increases the amount of phosphorylated StAR, thus 
increasing its activity (Arakane et al. 1997; Stocco et al. 2001; Sugawara et al. 1997). 
StAR facilitates steroid synthesis by importing cholesterol across the mitochondrial 
membranes for metabolism into pregnenolone, a building block for all other steroid 
hormones (Stocco 2001). Specifically, StAR imports cholesterol from the outer to the 
inner mitochondrial membrane, where cholesterol is converted to pregnenolone by 
cytochrome P4 5 0 side-chain cleavage enzyme (Devoto et al. 2001; Stocco 2001), 
hence making cholesterol import into the mitochondria the rate limiting step of all 
steroid production (Stocco 2001; Wiltbank et al. 1993).
Steroidogenic Acute Regulatory (StAR) Protein
StAR was first isolated and cloned in MA-10 mouse leydig cells (Clark et al.
1994). The -30 kDa StAR phosphoprotein is cleaved from larger -32- and -37 kDa 
precursors (Stocco and Sodeman 1991), which takes place in the mitochondria of 
steroidogenic cells. The 37- and 32 kDa precursors are the active forms of the protein 
that transport cholesterol from the outer to the inner mitochondrial membrane before 
they are processed to the 30 kDa protein (Stocco and Sodeman 1991). Once in the 
inner mitochondrial membrane, the 30 kDa protein loses contact sites and is no longer 
active in cholesterol transport (Pescador et al. 1996), however, it may remain 
associated with the inner membrane for a relatively long time.
Although StAR is paramount to cholesterol transport, there is evidence to 
suggest that StAR works in concert with several other molecules to facilitate this
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process. StAR may function as a triad with peripheral-type benzodiazepine receptor 
(PBR) and endozepine (Niswender 2002). Previous research linked PBR to 
cholesterol translocation in adrenocortical cells (Krueger and Papadopoulos 1990; 
Papadopoulos et al. 1990) and steroidogenesis in mouse ley dig cells (Krueger and 
Papadopoulos 1990; Papadopoulos et al. 1990). Using fluorescent energy transfer, 
recent research shows that PBR may contribute to StAR’s ability to transport 
cholesterol across the mitochondrial membrane (West et al. 2001).
StAR is associated with steroidogenic tissues of many species, including the 
rat (Epstein and Orme-Johnson 1991), rabbit (Townson et al. 1996), human (Devoto 
et al. 2001), bovine (Pescador et al. 1996), and sheep (Juengel et al. 1995). The StAR 
cDNA sequence remains highly conserved across evolution, with the bovine and 
human sequences sharing 84% homology (Sugawara et al. 1997). Bovine StAR is 
transcribed as 3 kb and 1. 8  kb transcripts, which differ only in their 3’polyadenylation 
sites. Both transcripts are highly expressed in the CL at mid to late cycle but are at 
low levels early in the cycle (Hartung et al. 1995). The human StAR gene is located 
on pi 1.2 of chromosome 8 , with the 37 kDa form of StAR containing 285 amino 
acids (Sugawara et al. 1997).
The StAR protein (Figure 3) contains three primary structural components, 
the StAR related lipid transfer (START) domain, the central portion, and the 
mitochondrial matrix targeting sequence (MMTS).
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Figure 3. Structural Domains of StAR 
C-terminus N-terminus
START MMTS
START: StAR related lipid transfer domain 
MMTS: Mitochondrial Matrix Targeting Sequence
The START domains of StAR are -210 amino acid lipid binding domains that have 
been implicated in intracellular lipid transport, lipid metabolism, and cell signaling 
events (Soccio and Breslow 2003). The MMTS is located on the N-terminus of the 
protein and is responsible for directing StAR to the mitochondria. Upon entering the 
mitochondria, cleavage of the 37 kDa form involves the removal of a 25 amino acid 
mitochondrial targeting sequence to generate the 30 kDa inactive form (Sugawara et 
al. 1997), which may be catalyzed by metal-dependent matrix proteases (Epstein and 
Orme-Johnson 1991). StAR concentrations are directly correlated to steroidogenesis 
rates and seem to be influenced by cAMP levels (Kohen et al. 2003), which may be 
regulated by PGF2a via the PKC and PKA pathways (Wiltbank et al. 1993; Wiltbank 
et al. 1991)
Luteolysis
If the ovum is not fertilized during the functional luteal phase of the estrous 
cycle, then the CL will regress (die) to allow a new cycle to commence, providing 
another chance for an ovum to be fertilized. The process of CL regression is known
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as luteolysis, the focus of my study. Luteolysis in estrous mammals is strongly tied 
with PGF2a and involves the actions of many protein mediators. In turn, these 
mediators participate in, (1) functional demise through the loss of P synthesis, and (2) 
structural demise which involves tissue degradation due in part to ECM remodeling.
Role of the Uterus in Luteolysis
The role of the uterus in CL regression was first reported by Leo Loeb (Loeb 
1923b; Loeb 1927) who demonstrated in guinea pigs that hysterectomy caused an 
extended lifespan of the CL. Similar findings were then reported in cyclic sheep and 
cows (Wiltbank and Casida 1956), rats (Bradbury 1937), and rabbits (Asdell and 
Hammond 1933). However, this only remains true for estrous cycling mammals and 
not primates (Beavis et al. 1969; Burford and Diddle 1936). With the persistence of 
the CL after hysterectomy, this suggested that the uterus possessed a component that 
facilitates luteolysis.
PGF2a Identified As the Mammalian Luteolysin
PGF2a is found in abundant quantities in the uterus and may play a role as a 
uterine luteolysin (Pharris and Wyngarden 1969). This information led to an ovarian 
autotransplant sheep model first established at the Worcester Foundation (McCracken 
et al. 1999). This model, originally established using the adrenal gland, involved 
removal of the ovary from the abdomen and subsequent attachment to the carotid 
artery and jugular vein of the neck as seen in Figure 4.
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FIGURE 4. Ovarian Autotransplant: Diagram of the technique for intra-arterial 
infusion of autotransplanted ovary in sheep and periodic collection of ovarian venous 
blood. With inflation of pneumatic cuff above carotid arterial pressure, carotid 




Venous catheter / Carotid artery
pneumatic c u r ^ ^ j
Jugular vein
Manual occlusion of jugular vein
ovarian venous blood
Adapted from (McCracken et al. 1969).
The transplanted ovary was then infused with PGF2a through the arterial 
supply, and the results mimicked that of natural luteolysis. However, when PGF2a 
was infused systemically, there was no effect on CL function (McCracken et al. 1972; 
McCracken et al. 1970). The negative results were explained in part by the dilution 
effect and the rapid metabolism of PGF2a by the lungs (Ferreira and Vane 1967). 
These negative results gave support to the belief that PGF2a must be the luteolytic 
hormone that was periodically released by the uterus, acting on the adjacent ovary to 
induce CL regression (McCracken et al. 1999). Furthermore, investigations using 
radiolabeled PGF2a suggest that diffusion of uterine PGF2a across blood vessel 
walls, in a counter-current exchange system, is sufficient to initiate luteolysis in sheep 
(McCracken et al. 1984)
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Luteolytic Effects of PGF2a
As mentioned earlier, PGF2a acts through a 7-transmembrane heterotrimeric 
G-coupled protein receptor to initiate biological responses. PGF2a initiates the 
decline of luteal function through several mechanisms. The first is the rate of 
cholesterol transport across the mitochondrial membrane, a crucial component to 
steroid synthesis. Cellular transport of cholesterol involves several molecular 
mediators, including the interactions of sterol carrier protein-2 (SCP-2) with the 
cytoskeleton, and the before mentioned StAR. PGF2a decreases expression of SCP-2 
(McLean et al. 1995) and drastically reduces expression of tubulin, a major 
component of microtubule fibers in sheep (Murdoch 1996). Evidence also suggests 
that StAR mRNA (Juengel et al. 1995) and protein (Pescador et al. 1996) is down- 
regulated following PGF2a treatment. Due to the fact that StAR protein only has a 
half-life of 3-5 minutes (Epstein and Orme-Johnson 1991), a reduction in StAR will 
lead to a sudden and drastic reduction of P synthesis.
Another fundamental step of luteal regression involves apoptosis, or 
programmed cell death. PGF2a is, in part, believed to initiate this process throughout 
luteolysis (Sawyer et al. 1990). Apoptotic cells have distinguishable characteristics 
including: nuclear and DNA fragmentation (oligonucleosome formation), formation 
of membrane bound vesicles, chromatin condensation, and cellular shrinkage 
(Eamshaw et al. 2000); all of which have been noted in luteal cells throughout 
luteolysis (Juengel et al. 1993; Zheng et al. 1994).
Another common feature of apoptosis is loss of cell adhesion to the ECM due 
to the decay of microtubule structures within the cell (Murdoch 1996). ECM stability
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is correlated to the balance of tissue inhibitors of metalloproteinases (TIMPs) and 
their enzymatic counter-parts, matrix metalloproteinases (MMPs) (see next section). 
Researchers suggest that TIMPs promote ECM preservation (Smith et al. 1999) and 
subsequent down-regulation of TIMPs throughout luteolysis could promote structural 
demise of the gland in response to PGF2a (Duncan et al. 1996; Mclntush et al. 1997; 
Towle et al. 2002). Although there are many immune and cytokine factors that have 
important roles in luteolysis, they are beyond the scope of this discussion.
Tissue Inhibitors of Metalloproteinases (TIMPs)
Tissue inhibitors of metalloproteinases (TIMPs) comprise a family of proteins 
that form tight specific and reversible non-covalent complexes with latent and active 
forms of MMPs in a 1:1 ratio (Bode and Maskos 2001). There are four known 
TIMPs that have been cloned and sequenced to date. Table 2 summarizes some basic 
features of these inhibitors.











TIMP-1 -29 Glycosylated Diffusible Xpl 1.3-11.23 0.9
TIMP-2 -19-21 Unglycosylated Diffusible 17q25 3.5 and 1
TIMP-3 -24-27 Glycosylated ECM
bound
22ql2.1-13.2 4.5, 2.8, 
2.4
TIMP-4 -23-24 Unresolved Diffusible 3p25 1 . 2
Adapted from (Greene et al. 1996; Salamonsen and Wool ey 1996)
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These TIMPs share only 40% homology in their cDNA sequence (Douglas et 
al. 1997), suggesting that each TIMP has a distinct identity, even though all TIMPs 
can bind active MMPs. All four TIMPs have 12 cysteine residues in common, 
forming six disulfide bonds that segregate both the C- and N-terminal domains with 
three disulfide bonds each (Williamson et al. 1990). The N-terminal domain is the 
portion of all TIMP proteins that interacts with the catalytic domain of MMPs which 
leads to inhibition of MMP enzymatic activity (Woessner and Nagase 2000). The 
variability of the C-terminus may contribute to preferred inhibition of MMP targets 
(Bode and Maskos 2001).
TIMP-1 is an -28.5 kDa N-linked glycoprotein (Gasson et al. 1985) that 
inhibits all known MMPs (Edwards 2001). The C-terminal domain of TIMP-1 
preferentially binds MMP-9 at the hemopexin domain (Goldberg et al. 1989). TIMP- 
2 is an -19 kDa protein that, unlike other TIMPs, has an extended C-terminal domain 
that is negatively charged (Murphy and Willenbrock 1995) and preferentially binds 
MMP-2 (Goldberg et al. 1989). TIMP-3 is an N-glycosylated protein that varies in 
molecular mass (24-27 kDa) depending on the degree of glycosylation (Apte et al.
1995). TIMP-3 is the only TIMP that is strongly associated with the ECM (Leco et 
al. 1994) and preferentially binds MMP-1, -2, -3, -9, and -13 (Apte et al. 1995). 
TIMP-4 is an -24 kDa protein and its glycosylation state is unknown. TIMP-4 is 
suggested to be an important regulator of ECM turnover (Leco et al. 1997) due to the 
fact that TIMP-4 binds MMP-1, -2, -3, -7, -8 , -9, -12, -13, and -14 (Stratmann et al. 
2001a; Stratmann et al. 2001b).
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Other TIMP Functions
TIMPs have a large role in regulating ECM remodeling and homeostasis, 
however, they possess a variety of other functions. Evidence suggests that TIMPs 
regulate MMP activity and activation by forming TIMP/proMMP complexes (Wang 
et al. 2000). TIMP-1 has also been associated with the proliferation of endothelial 
cells and fibroblasts, thus acting as a pseudo growth factor (Hayakawa et al. 1992). 
Further, TIMP-1 stimulates steroidogenesis in both ley dig and granulosa cells 
(Boujrad et al. 1995). Although there has been no direct link between TIMP-1 and 
StAR expression, they share a partial (124 base pairs) homologous DNA sequence 
(Hartung et al. 1995). This relationship has yet to be fully elucidated.
Matrix Metalloproteinases (MMPs)
The matrix metalloproteinases (MMPs) are a family of zinc and calcium 
dependent proteolytic enzymes that collectively digest all ECM components 
(Birkedal-Hansen 1995b). MMPs are classified into groups based on their preferred 
matrix protein substrate (Birkedal-Hansen 1995a; Matrisian 1990). Currently there 
are 26 known MMP family members composing 6  classification groups (Table 2): 
collagenases, gelatinases, stromelysins, MT-MMPs (membrane type), matrilysins, 
and other type (Johnson et al. 1998; McCawley and Matrisian 2001). These MMPs 
regulate ECM remodeling, and thus mediate cellular events such as cell proliferation, 
migration, differentiation and apoptosis (Smith et al. 1999; Stemlicht and Werb
2001). These enzymes typically demonstrate low activity in normal tissues, but are 
activated/upregulated during inflammation and physiological remodeling processes
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(Johnson et al. 1998). These processes include follicular growth, ovulation, 
luteinization, luteolysis, menstruation, and placental development (Smith et al. 2002).
MMP Characteristics
There are several domains preserved in all MMPs. They are: (1) the signal 
peptide domain, which directs the enzyme to the rough ER during synthesis; (2) the 
propeptide domain, which maintains latency until activation; (3) the catalytic domain, 
which contains a highly preserved zinc (Zn2+) binding region; (4) the hemopexin 
domain, which determines substrate specificity; and (5) the small hinge region, which 
enables the hemopexin region to present substrate to the active core of the catalytic 
domain. The MT-MMPs possess an additional transmembrane domain containing 
-20 hydrophobic amino acids and a 24 amino acid intracellular domain (Bode and 
Maskos 2001; Stemlicht and Werb 2001). These MMP domains are configured in a 
way that makes the zymogen form of the enzyme more stable.
MMP Families
As mentioned earlier, there are six classifications of MMPs, categorized by 
substrate preferences. Currently the subsets of MMP families are: (1) collagenases, 
including MMP-1, MMP-8 , MMP-13; (2) gelatinases; including MMP-2, and MMP- 
9; (3) stromelysins, including stromelysin-1 and -2; (4) membrane type 
metalloproteinases (MT-MMPs), including MT1-6 MMP; (5) matrilysins, containing 
MMP-7 and MMP-26; and (6 ) other MMPs, including MMP-19, MMP-18, and 
MMP-7, with most still being characterized. Currently the MMP family consists of at
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least 26 MMPs. Table 3 shows the families and characteristics of MMPs (not all 
discussed in this review).
Table 3. Matrix Metalloproteinase Family Characteristics
Subfamilies Trivial Name MMP # Molecular mass 
(kDa)
Chromosome localization
.atent Active Human Mouse
Collagenase-1 MMP-1 52 42 Ilq22-q23
Collagenases Collagenase-2 MMP- 8 85 64 Ilq 2 1 -q2 2
Collagenase-3 MMP-13 52 42 1 Iq22.3 9(A1-A2)
Collagenase-4 MMP-18 53 42
Gelatinases Gelatinase A MMP-2 72 6 6 16ql3 8(42.9)
Gelatinase B MMP-9 92 84 2 0 ql 1.2-ql3.1 2(H1-H2)
Stomelysins Stromelysin-1 MMP-3 57 45 1 lq23 9(1.0)
Stromelysin-2 MMP-10 54 44 Ilq22.3-q23
MT-MMP MT-MMP 1 MMP-14 6 6 54 14qll-q!2 14(12.5)
MT-MMP2 MMP-15 72 60 16ql3-q21 8(45.5)
MT-MMP3 MMP-16 64 53 8 q2 1 4(3.6)
MT-MMP4 MMP-17 57 53 12q24.3 5(1.0)
MT-MMP5 MMP-24 73 62 2 0 ql 1 .2 -ql2 2 ( 1 .0 )
MT-MMP6 MMP-25 63 62 16pl3.3
Matrilysins Matrilysin-1 MMP-7 28 19 Ilq 2 1 -q2 2 9(1.0)
Matrilysin-2 MMP-26 29 19 llp l5
Other MMPs Stromelysin-3 MMP-11 64 46 2 2 ql 1 . 2 10(40.9)
Metalloelastas< MMP-12 54 2 2 Ilq22.2-q22.3 9(1.0)
RASI-1 MMP-19 54 45 12ql4 10(71.0)
Enamelysin MMP-20 54 2 2 llq22.3 9(1.0)
XMMP MMP-21 70 53
CMMP MMP-22 51 43 1 lq24
CA-MMP MMP-23 44 31 1 lp36.3
Epilysin MMP-2 8 59 45 17ql 1 . 2
Adapted fronl (McCawley anc Matrisian 21301; Siriith et aI. 1999).
34
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Gelatinases
Since the MMP family is so large, a complete description of each individual is 
beyond the purview of the present review. Thus, this discussion is limited to the 
gelatinases A & B, also known as MMP-2 & MMP-9, respectively. Gelatinases 
degrade collagens type IV and V, in addition to gelatin, a byproduct of denatured 
collagen (Matrisian 1990; McCawley and Matrisian 2001). The gelatinases are 
among the most highly researched MMPs due to their roles in degradation of 
basement membrane components. Gelatinase activity was first detected in 
rheumatoid synovial fluid in 1972 (Harris and Krane 1972). Initial experiments 
suggested that gelatinases digest soluble type IV collagen (Liotta et al. 1979; Murphy 
et al. 1981). This activity remains questionable because neither MMP-2 nor MMP-9 
degrade full-length type IV collagen (Mackay et al. 1990). However, gelatinases are 
characterized by three repeats of type II fibronectin-like gelatin binding regions, 
which enable them to bind to the denatured form of collagen (O'Farrell and 
Pourmotabbed 1998). Gelatinases are of great interest due to their roles in cancer 
(Liotta et al. 1979), luteal regulation (Goldberg et al. 1996), and many other 
reproductive and pathological processes (Birkedal-Hansen 1995b; Birkedal-Hansen et 
al. 1993; Hulboy et al. 1997).
Gelatinase A: MMP-2
Gelatinase A, also known as MMP-2 is an -72 kDa protein in its latent form 
that is cleaved to its -62 kDa active form via a membrane-dependent mechanism 
(Brown et al. 1990). MMP-2 degrades gelatin, type IV, type I (Aimes and Quigley
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1995), type V (Okada et al. 1990), type VII (Seltzer et al. 1989), and type X (Welgus 
et al. 1990) collagens as well as numerous other components of the ECM such as 
elastin and laminin (Giannelli et al. 1997; Senior et al. 1991). This wide range of 
substrates enables MMP-2 to participate in a variety of cellular processes, including 
cell proliferation, differentiation, adhesion of cells to the ECM, and cellular 
migration. Due to these actions, MMP-2 is thought to have a significant role in tumor 
invasion (Brown et al. 1990), angiogenesis (Brooks 1996), and Alzheimer’s disease 
(LePage et al. 1995).
MMP-2 is constitutively expressed in most cell types (Yeow et al. 2001) and 
its transcription appears to be only mildly induced or repressed (2-4 fold), (Huhtala et 
al. 1991) compared to other MMPs that can be more significantly induced (up to 100 
fold) (Brown et al. 1990). This suggests that MMP-2 regulation is primarily 
controlled by extracellular activation or inhibition by TIMPs. Pro-MMP-2 is often 
associated with TIMP-2 at their respective C-termini (Goldberg et al. 1989). A 
proposed mechanism of activation couples proMMP-2 and TIMP-2, with the N- 
terminus of TIMP-2 bound to MT1-MMP (Butler et al. 1998). Upon binding, MT1- 
MMP becomes inactivated, however, other local MTl-MMPs activate the associated 
MMP-2 molecule through cleavage of the N-terminus of proMMP-2, thus revealing 
the zinc-dependent active site (Butler et al. 1998; Hemandez-Barrantes et al. 2000). 
MMP-1 (Crabbe et al. 1994a) and MMP-7 (Crabbe et al. 1994b) have also been 
linked to MMP-2 activation through cleavage of the proMMP-2 N-terminus. MMP- 
2 then in turn is capable of binding and activating other MMPs such as proMMP-1, 
proMMP-2 (Crabbe et al. 1994a), and proMMP-13 (Knauper et al. 1996).
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Gelatinase B: MMP-9
Gelatinase B, also known as MMP-9 is an -92 kDa protein in its latent form 
that is cleaved to its -84 kDa active form via a membrane-dependent mechanism 
(Brown et al. 1990). It is processed with N- and O-linked glycosylation (Murphy et 
al. 1994). Like MMP-2, MMP-9 degrades gelatin, type IV, and type V collagens. 
MMP-9 is more effective than MMP-2 at degrading type V collagen, however, MMP- 
9 is incapable of degrading type I collagen or fibronectin (Yu et al. 1998). MMP-9 
was first characterized in rabbit bone culture medium (Murphy et al. 1981) and in 
human and porcine neutrophils (Murphy et al. 1981).
Much like MMP-2, MMP-9 is secreted as a proMMP-9/TIMP-l complex 
associated at the C-terminus (O'Connell et al. 1994; Ward et al. 1991). The activation 
of MMP-9 depends on its association with TIMP-1, meaning that MMP-9 only 
undergoes one cleavage when bound to TIMP-1. When TIMP-1 is not bound, MMP- 
9 undergoes a series of cleavages from the C-terminus to result in -67 kDa and -83 
kDa forms. If there is no association with TIMP-1, then MMP-3 processes the active 
-67 kDa form to an inactive -50 kDa form (Shapiro et al. 1995). ProMMP-9 is 
activated by MMP-1, MMP-7, MMP-2 (Fridman et al. 1995), mast cell chymase 
(Fang et al. 1996), trypsin, MMP-3, and cathepsin G (Okada et al. 1992). In addition 
to cytokine stimulation, MMP-9 can be upregulated by component fragments of the 
ECM, such a laminin and fibronectin (Corcoran et al. 1995; Huhtala et al. 1991)
Unlike MMP-2, MMP-9 is only constitutively expressed by several tissues 
including neutrophils, macrophages, osteoclasts, and trophoblasts. MMP-9 is found 
in high levels in physiological processes and pathologic conditions such as bone
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development (Engsig et al. 2000; Vu and Werb 2000), implantation (Reponen et al.
1995), and inflammation (Leppert et al. 1995). It is strongly believed that MMP-9 
helps to regulate physiological responses such as inflammation, tissue injury and 
tissue remodeling and may play a role in subendothelial basement membrane 
reorganization, allowing immune cell infiltration into an area (Vu and Werb 2000; 
Werb et al. 1996).
MMPs and TIMPs in the CL
Since the CL is a unique tissue that undergoes routine formation and 
regression, the turnover and remodeling of the ECM must be tightly controlled. It is 
believed that ECM remodeling and reorganization is controlled, in part, by the 
balance between TIMP and MMP activity. In vitro studies using follicle and luteal 
cells demonstrated that ECM components direct differentiation, particularly follicular 
to luteal cells, and that loss of ECM may cause apoptosis and dedifferentiation (Smith 
et al. 1999; Stemlicht and Werb 2001).
MMPs and TIMPs in the CL
During the estrous cycle, TIMPs and MMPs play important roles in luteal 
angiogenesis, CL growth and development, and luteolysis. Several TIMPs and 
MMPs have been characterized in the ovaries of several species. TIMP-1 is a major 
secretory product of the sheep CL shortly following ovulation, particularly days 3-10 
of the estrous cycle (Smith et al. 1994a; Smith et al. 1994b). TIMP-2 also is 
expressed at its highest levels early in CL development, days 3-7 (Smith et al. 1994b;
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Zhang et al. 2003). Evidence shows that TIMPs, particularly TIMP-1, may be a 
stimulator of cell proliferation of various cell types within the CL, and 
steroidogenesis, particularly in LLCs, where TIMP-1 mRNA is found in 
concentrations up to 15 times higher than in SLCs (Smith et al. 1994b). Likewise, 
TIMP-1 has been found to stimulate steroidogenesis in rat ley dig cells and granulosa 
cells (Boujrad et al. 1995). TIMPs have also been linked to luteinization (Edwards et 
al. 1996; Nothnick et al. 1997). In turn, evidence suggests that these proteins, 
particularly TIMP-1, may be under hormonal control (O'Sullivan et al. 1997).
In rats, MMPs are found at their highest levels in the early stages of CL 
development compared to any other stage (Nothnick et al. 1996). A possible link is 
suggested between MMP activity allows for blood vessel formation and successful 
CL development (Goldberg et al. 1996; Zhang et al. 2002). It has also been 
determined that deficient levels of MMP-2 lead to reduced fertility. This was 
demonstrated in ewes when immunization with an MMP-2 antibody led to incomplete 
formation of the CL (Gottsch et al. 2001). During CL formation, intense tissue 
remodeling occurs, which explains the increased expression of MMP-2, MMP-9, and 
MMP-1 in the mid stage porcine CL (Pitzel et al. 2000). As the CL wanes, P 
concentrations correlate to MMP expression. For example, MMP-2, MMP-9, and 
MMP-13 levels increase dramatically following a decrease in peripheral P levels 
(Duncan et al. 1998; Liu et al. 1999; Towle et al. 2002), suggesting a role for these 
enzymes in luteolysis.
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Summary
In the developing CL there is a tight balance between TIMPs and MMPs that 
promote the rapid growth of the tissue. Following this rapid period of growth, it 
appears that the expression of some luteal TIMPs decrease while MMP expression 
increases, coinciding with peripheral P decline associated with the action of PGF2a. 
In the following chapter, select functional (COX-1, COX-2, StAR, P) and structural 
(TIMP-1, TIMP-2, MMP-2, MMP-9) mediators of luteolysis are investigated. 
Specifically, the goal of the present study is to use an established in vivo model to 
determine the temporal relationship among these mediators following two sequential 
pulses of PGF2a during luteolysis in sheep.
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CHAPTER II
TEMPORAL EXPRESSION OF PROTEIN MEDIATORS DURING PGF2a- 
INDUCED LUTEOLYSIS IN SHEEP
Introduction
The corpus luteum (CL) is an ephemeral endocrine gland that is crucial for 
reproduction. The functionality of the CL is marked by the production of the steroid 
hormone progesterone (P), which is necessary for successful implantation of the 
embryo and maintenance of pregnancy in most mammals (Ellicott and Dziuk 1973). 
If pregnancy does not occur, the CL undergoes luteolysis, a process that is initiated by 
prostaglandin F2a (PGF2a). Defects in luteal function have been associated with 
infertility, abortion, and ovarian cycle disorders (Niswender et al. 2000).
It was determined in the 1970’s that PGF2a is the primary agent responsible 
for initiating luteolysis in estrous cycling animals (McCracken et al. 1972; 
McCracken et al. 1970). This notion was first indicated by the prolonged lifespan of 
the CL after removal of the uterus (hysterectomy) in guinea pigs (Loeb 1923a), and 
further supported by work showing that the uterus is a primary source of endogenous 
PGF2a responsible for initiating luteolysis in estrous cycling animals (McCracken et 
al. 1972). Luteolysis has been described as a two step process: a decline in P 
production that leads to functional demise, and luteal involution that leads to 
structural regression (Diaz et al. 2002; McCracken et al. 1999)
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In the sheep, luteolysis is caused by a sequential series of four to five one- 
hour-long pulses of uterine PGF2a, which activates a cascade of events that 
ultimately result in the functional and structural demise of the CL (McCracken et al. 
1999). This pulsatile infusion of PGF2a induces luteolysis with only 1 /40th of the 
amount required when given by continuous infusion (Schramm et al. 1983). Thus, in 
order to study progressive biochemical changes within the CL in vivo, a model was 
established in which sheep, during the mid-luteal phase, received systemic infusions 
of PGF2a (20ug/min/lhr) at intervals mimicking the frequency of PGF2a pulses at 
the onset of natural luteolysis. This dosage provides enough PGF2a systemically to 
escape metabolism by the lung to a point equivalent to physiological conditions.
We have successfully used this physiological model to determine dynamic 
changes in the protein expression of several molecular mediators of luteolysis after a 
1 hr infusion of PGF2a (Allen et al. in review; Towle et al. 2002). Specifically, we 
reported that TIMP-1 and TIMP-2 proteins decreased drastically at 1 hr, which was 
accompanied by an increase in MMP-2 activity at 4 and 8  hrs following PGF2a 
infusion. The increase in MMP-2 at 8  hrs was coupled with a nadir in StAR and 
peripheral plasma progesterone (P) concentrations. In addition, there was a delayed 
induction of COX-2 protein at 16 and 24 hrs following PGF2a infusion.
Collectively, these data provided the impetus for the present study, which was 
to determine the response of these proteins following two 1 hr infusions of PGF2a. 
We chose to continue monitoring the zinc- and calcium-dependent enzymes, matrix 
metalloproteinases (MMPs), and their inhibitors (TIMPs) because of their influence 
on the structural remodeling of the extracellular matrix (ECM). The ECM influences
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cellular processes such as migration, differentiation, gene expression, and apoptosis 
(Ricke et al. 2002a). Furthermore, in domestic ruminants, luteolysis is marked by 
loss of cell adhesion to the ECM and loss of progesterone synthetic capacity (Ricke et 
al. 2002b). Besides the MMPs and TIMPs, we also monitored other proteins that 
mediate luteal function. These mediators include the cyclooxygenase (COX) 
enzymes -1 and -2, and steroidogenic acute regulatory protein (StAR). Prostaglandin 
endoperoxidase H synthases, or COX, are membrane bound enzymes (Smith and 
Dewitt 1996) capable of both peroxidase and oxygenase activity (Smith et al. 1996). 
These combined activities convert arachidonic acid to produce PGG2 (Smith and 
Dewitt 1996; Smith et al. 1996), a precursor of PGF2a. In response to PGF2a, the 
CL upregulates COX synthesis (and thus prostaglandin production) in a amplification 
and positive feedback manner (Tsai and Wiltbank 1997).
Another protein of interest is StAR, which is central to steroidogenesis. StAR 
transports cholesterol from the cytoplasm across the mitochondrial membranes 
(Stocco 2001), thus providing substrate for the steroidogenic pathway . In the porcine 
CL, StAR protein expression is decreased after PGF2a treatment (Diaz and Wiltbank 
2005).
Therefore, to gain further insight into the temporal response of the sheep CL 
to PGF2a, the specific objective of our study was to determine the protein expression 
patterns of TIMP-1 and TIMP-2, COX-1 and COX-2, and StAR after two pulses of 
PGF2a.
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Materials and Methods 
Animal Model o f PGF2a-Induced Luteolysis
To mimic the physiological onset of luteolysis in sheep, a single 1 hr systemic 
infusion of PGF2a (-.22 pg/kg/min) can be administered at mid-cycle (Custer et al.
1995). This rate of infusion provides a sufficient level of PGF2a that reaches the 
ovary even after metabolism by the lungs, resulting in a 40% decline in P (Towle et 
al. 2002). This decline in P levels is similar to that seen following an endogenous 
pulse of PGF2a (Zarco et al. 1988). This established model was used to study the in 
vivo changes in molecular mediators of luteolysis following two systemic infusions 
of PGF2a, with the second infusion given 16 hrs after the first.
Tissue Collection and Preparation
Luteal tissue was collected and prepared as previously described (Towle et al.
2002). A group of mixed Suffolk and Dorset ewes (Ovis aries; approximately 90 kg) 
were housed at the University of Connecticut (Storrs, CT) and their estrous cycles 
synchronized using two intramuscular injections of Lutalyse (5mg; Upjohn Co.; 
Kalamazoo, MI) given at 4 hour intervals. Ewes were observed twice daily for estrus 
using a vasectomized ram following treatment (Day 0 = estrus). On the eleventh day 
post estrus ewes were placed in metabolism cages and 16 gauge cannulae were 
inserted into both jugular veins, while under local anesthesia (2 % [w/v] lidocaine). 
Two 1 hr systemic infusions of PGF2a (Upjohn Co.) were administered, 16 hrs apart 
to mimic endogenous frequency, to the right jugular vein via a Harvard Infusion 
Pump (model no. 600-910/920; Harvard Apparatus Co.; Holliston, MA) at a rate of
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20 pg/min (Custer et al. 1995). Control animals received no treatment. CL were 
removed surgically via flank laparotomy under local anesthesia (2 % lidocaine) before 
the second PGF2a infusion, designated as time 0 (controls), and 1, 8 , 16, and 24 hrs 
post PGF2a infusion (n=4 sheep for each time point; see Figure 5). All experimental 
animal procedures received prior approval by the University of Connecticut Animal 
Care and Use Committee. After collection, luteal tissue was immediately placed on 
dry ice, and stored at -80°C. For analysis, individual samples representing each of the 
five time points were analyzed in series (n=4).
Protein Extraction
Luteal tissue proteins (TIMP-2, StAR, COX-1, and COX-2) were extracted 
with a buffer (50mM Tris-HCl, 150mM NaCl, 0.02% [w/v] sodium azide, lOmM 
EDTA, 1% [v/v] Triton X-100, pH 7.4) containing protease inhibitors (1 pg/ml 
AEBSF, 1 pg/ml pepstatin A, 10pg/ml aprotinin) in a ratio of lg tissue : 8 ml 
extraction buffer, as previously described (Zhang et al. 2002). Tissue was 
homogenized with a Kinematica Polytron, and the homogenate was then sequentially 
centrifuged at 800 x g for 10 minutes and at 10,000 x g for 10 minutes at 4°C. The 
supernatant between the pellet and fat layer was then removed and stored at -20°C 
until used for immunoblot analysis of TIMP-2 and StAR. For COX-1 and COX-2 
analysis, a portion was removed after homogenization, and sonicated twice for 5 
seconds (Sonifier Cell Disruptor 350, Branson Sonic Power Co.) prior to 
centrifugation, as described above. Complete extraction protocols are found in 
Appendix A.
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Luteal TIMP-1, MMP-2, and MMP-9 proteins were extracted in 2 M NaCl, 
0.01M HEPES, 0.02% NaN3, pH 7.6, as previously described (Moses et al. 1990; 
Murray et al. 1986; Towle et al. 2002). Briefly, conditions were normalized using an 
8:1 (v/w) ratio of extraction buffer to tissue (8 ml:lg). Samples were minced with 
scalpel blades and homogenized before being placed on a Clay Adams Nutator Mixer 
(Beckton Dickinson, Sparks, MD) to extract for 24 hours at 4°C. Extracts were then 
centrifuged initially at 2,500 x g  followed by a final centrifugation at 15,000 x g  to 
further remove debris. Afterwards, the samples were ultrafiltered through Amicon 
Ultra 4 concentrators (10,000 M.W.C, Amicon, Beverly, MA) at 3,500 x g  before 
dialysis with CAB+ buffer (0.2M NaCl, ImM CaCl2, 50mM Tris, 0.02% NaN3, pH
7.6). The samples were ultimately concentrated 4-fold before storage at 4°C until 
analysis. Details are in Appendix B.
Protein Determination (Bradford Assay)
Protein concentrations were determined by the Bradford Method (Bradford 
1976) using Coomassie Blue. Bovine serum albumin (Sigma; St. Louis, MO) 
dissolved in CAB+ buffer (0.2M NaCl, ImM CaCl2, 50mM Tris, 0.02% NaN3, pH
7.6) was the protein standard. Optical densities were read at 595nm using a 
spectrophotometer (model DU640; Beckman Instruments; Fullerton, CA). All luteal 
tissue protein samples were diluted 1:10 or 1:20 with CAB+ buffer and assayed in 
triplicate. Details are in Appendix C.
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Immunoblot Analysis
Equivalent amounts of luteal tissue protein extracts were loaded on SDS- 
PAGE gels (10% [w/v] for COX-1, COX-2, TIMP-1 and TIMP-2, and 12.5% [w/v] 
for StAR). Except for TIMP-1, all were run under reducing conditions, (5% [v/v] 2- 
mercaptoethanol, 100°C for 5 minutes), at 150 V for 45-60 minutes, along with the 
dual color, prestained SDS-PAGE marker standards (Bio-Rad Laboratories, Hercules, 
CA, USA). Separated proteins were transferred to a Protran nitrocellulose membrane 
(Schleicher & Schuell; Whatman Group; Keene, NH, USA) for 2 hrs at 200mA. 
Non-specific binding was blocked with 5% [w/v] non-fat dried milk in TBST buffer 
(0.01 M Tris-HCl, 0.15M NaCl, 0.05% [v/v] Triton X-100, pH 8.0) for either 2 hrs 
(COX-1 and COX-2) or 1 hr (StAR, TIMP-1, and TIMP-2) at room temperature. See 
Appendix D for immunoblot and zymography recipes. Respective primary 
antibodies were then added, and allowed to incubate either overnight at 4°C (COX-1, 
COX-2, TIMP-1, and TIMP-2) or for 1 hr at room temperature (StAR). The 
membrane was then washed with TBST buffer before incubation with a secondary 
antibody for 1 hr at room temperature. Following TBST washes, blots were 
visualized using an enhanced chemiluminescent (ECL) detection system (SuperSignal 
West Pico Chemiluminescent Substrate, Pierce). The blots were exposed to Kodak 
XAR-5 film (Eastman Kodak Co., Rochester, NY, USA), which was developed with 
a Konica (Wayne, NJ, USA) automatic developer. Each sample was run in duplicate. 
Two negative controls were performed for each protein; one with either normal 
mouse or rabbit non-specific IgG in lieu of primary antibody, and the second was 
exclusion of the primary antibody. Details are in Appendix E.
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Immunoblot Antibodies and Positive Controls
All COX antibodies and proteins were purchased from Cayman Chemical (Ann 
Arbor, MI, USA). The COX-1 monoclonal antibody was used at a concentration of 
4pg/ml, and was raised in mice against purified ovine COX-1. An ovine recombinant 
COX-1 protein (0.5pg) served as the positive control. The COX-2 polyclonal 
antibody, used at 1:1000, was raised in rabbits against a synthetic peptide from the C- 
terminus region of mouse COX-2, and cross-reacts with ovine, murine, and rat COX- 
2, but does not cross-react with COX-1 (Tsai and Wiltbank 1997). An ovine COX-2 
recombinant protein (0.5pg) served as the positive control. The StAR protein 
polyclonal antibody (1:1000) was a generous gift from Dr. Douglas Stocco (Texas 
Tech University, TX, USA). The antibody was raised in rabbits against a synthetic 
peptide created from amino acids 88-98 of the mouse StAR protein (Clark et al. 1994). 
The bovine CL was used as a positive control, co-migrating with the 30 kDa protein in 
each sample (Pescador et al. 1996). The TIMP-1 and TIMP-2 primary antibodies were 
purchased from Oncogene Research Products (Cambridge, MA). The TIMP-1 
monoclonal antibody was raised in mice against human TIMP-1 and was used at a 
concentration of 1 pg/ml (Cat# IM32L). The TIMP-2 monoclonal antibody was also 
raised in mice against human TIMP-2 and was used at a concentration of 5 pg/ml (Cat# 
IM56). Furthermore, a recombinant bTIMP-1, or a human TIMP-2 protein standard 
(Oncogene Research Products; Cambridge, MA) was included where appropriate. The 
secondary antibodies were immunoglobulin G conjugated to horseradish peroxidase 
(Pierce, Rockford, IL, USA). Anti-rabbit secondary antibody (1:10,000) was used for
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StAR and COX-2 immunoblots, while anti-mouse (1:10,000) was used for COX-1, 
TIMP-1, and TIMP-2 immunoblots.
Gelatin Zymography
Zymography was used to detect gelatinase (MMP-2 and MMP-9) activity using 
previously described methods (Towle et al. 2002) with minor modifications. Luteal 
extracts were mixed 1:1 with sample buffer (10% SDS, 4% sucrose [w/v], 0.1% 
bromophenol blue [w/v], 0.25M Tris, pH 6.8) and electrophoresed under non­
reducing conditions at -200 volts, using the Mini-Protean II system (Bio-Rad, 
Melville, NY) in 10% polyacrylamide gels containing 0.05% gelatin. Gels were then 
washed twice (15 minutes each) in 2.5% Triton X-100 (v/v) to remove SDS, rinsed 
with distilled water and incubated for 17-18 hours at 37°C in substrate buffer (5mM 
CaCL, 50mM Tris, pH 8.0). After incubation, gels were stained with Coomassie Blue 
R250 solution (0.5% in a 1:3:6 ratio of acetic acid, isopropanol, distilled water) for 30 
minutes and destained with distilled water for 2 days. MMP activity was observed as 
zones (bands) of clearance against the blue background of the gel. Adjacent lanes 
contained Perfect Protein markers (Novagen, Madison, WI) and the positive control, 
HT-1080 (Cat# CCL-121; American Type Culture Collection; Manassas, VA), which 
is conditioned medium of a human fibrosarcoma cell line known to produce several 
MMPs (e.g., MMP-2 and MMP-9, as well as TIMPs (e.g., TIMP-1 and TIMP-2). 
Details are in Appendix F.
To verify that the bands of clearing were the result of metal-dependent 
proteinases (MMPs), gels were incubated in substrate buffer containing 1,10- 
phenanthroline (lOmM; Sigma; St. Louis, MO). Latent and active forms of the
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MMPs were distinguished by incubating the samples with 2mM p- 
aminophenylmercuric acetate (APMA; Sigma; St. Louis, MO) for two hours prior to 
electrophoresis.
Quantification and Statistical Analysis
Photographic films of immunoblots and zymograms were densitized using UN- 
SCAN-IT version 6.1 (Silk Scientific Industries, Orem, UT, USA). Total pixel counts 
for every sample duplicate at each time point for individual sheep were determined, 
and averaged before analysis of variance was performed using the General Linear 
Model (GLM) subroutine of the Statistical Analysis System [SAS Institute Inc., 
1989]. Differences in the treatment means were evaluated with least square 
differences (LSD) with appropriate corrections for multiple comparisons. A value of 
p <0.05 was considered to be significant.
Results
Analysis of TIMPs and MMPs
As for the ECM mediators, immunoblotting revealed the presence of an -30 
kDa protein, consistent with the reported Mr of TIMP-1 and which also co-migrated 
with the TIMP-1 recombinant protein (Fig. 6). TIMP-1 expression decreased 60% 
(p<0.05) at 1 hr before recovering by 8 hrs and reaching a 30% increase (p<0.05) at 
24 hrs. A TIMP-2 protein was also identified in all samples, co-migrating with a 19 
kDa human TIMP-2 protein standard (Fig. 7). Like TIMP-1, TIMP-2 protein levels 
decreased by nearly 90% (p<0.05) by the 1 hr time point and remained low 
throughout the 24 hr sampling period.
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Gelatinase (MMP-2 and MMP-9) activity was identified by zymography in all 
samples. Besides co-migration with the HT-1080 positive control, true MMP activity 
was verified with 1,10-phenanthroline, while latent and active species were 
distinguished after incubation with APMA (data not shown). In sheep CL, active 
MMP-2 (-64 kDa), latent MMP-2 (-70 kDa), and active MMP-9 (-85 kDa) were 
identified (Fig. 8). Active MMP-2 increased (p<0.05) at the 1 hr time point before 
returning to basal levels by 8 hrs, while latent MMP-2 did not change at any time 
point (p>0.05). MMP-9 displayed a rising, but non-significant (p>0.05) trend 
towards the later time points.
Analysis o f COX enzymes
In all luteal tissue samples, visual observations of immunoblots revealed an 
-70-kDa protein, which co-migrated with a COX-1 recombinant protein (Fig. 9) and 
a single ~72-kDa protein, which co-migrated with a COX-2 recombinant protein (Fig. 
10). Densitometric analysis revealed no change (p>0.05) in the protein expression of 
COX-1 or COX-2 protein over time.
Analysis o f StAR and Progesterone
In all ovine luteal tissue samples, immunoblotting revealed an ~30-kDa 
protein, which co-migrated with the previously characterized StAR protein from 
bovine luteal tissue (Pescador et al., 1996) (Fig. 11). Peripheral progesterone 
concentrations (Fig. 12) displayed a 40% decline by 8 hrs before rising above pre­
infusion control levels at 24 hrs following two systemic infusions of PGF2a.
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Discussion
The ovine physiological model used in this study allowed us to determine the 
temporal expression of protein mediators during the onset of PGF2a induced 
luteolysis. The molecular mediators chosen in this study are considered to participate 
or serve as indicators of functional and structural demise of the CL. Previously, we 
have used this model to study dynamic in vivo changes in TIMP and MMP (Towle et 
al. 2002), and COX and StAR (Allen et al. in review) protein expression after a single 
infusion of PGF2a. In the present study, we examined the response of these same 
molecular mediators following a second 1 hr systemic infusion of PGF2a. Thus, this 
provides a unique opportunity to assess successive changes that occur in the CL 
during the early stages of luteolysis. At this point, it is important to mention that two 
physiological pulses/infusions of PGF2a are not sufficient to induce luteolysis 
(McCracken et al. 1999).
PGF2a of uterine origin is the luteolysin in sheep, and is known to stimulate a 
number of biochemical pathways that mediate both structural and functional 
regression (McCracken et al. 1999). Evidence suggests that very low concentrations 
of uterine PGF2a may be adequate to stimulate luteolysis (McCracken et al. 1984) 
through an auto-amplification feedback loop that upregulates luteal PGF2a, which is 
mediated by cyclooxygenase (COX) enzymes via PKC activation and Ca++ 
mobilization (Wu and Wiltbank 2001a). This positive feedback system may act in an 
autocrine manner to inhibit P production by the large luteal cells (LLCs) and the 
subsequent loss of function of the CL (Wu and Wiltbank 2001b). Indeed, we 
previously reported that COX-1 protein expression was unchanged, while COX-2 was
52
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
upregulated approximately 300% by 24 hrs after a single systemic infusion of PGF2a 
(Allen et al. in review). Interestingly, in the current study, COX-2 protein expression 
did not appear to change within the 24 hr sampling period following a second 
infusion of PGF2a. This could be explained by the fact that COX-2 protein levels are 
already elevated 300% following a single 1 hr infusion of PGF2a, suggesting that 
COX-2 protein may have already reached maximal expression following a single 
infusion of PGF2a (Fig 10, Fig 13).
In addition to a delayed induction of COX-2 expression, PGF2a depresses P 
synthesis. Peripheral P concentrations declined 40% at 8 hrs following a single 
infusion of PGF2a (Towle et al. 2002), which parallels the drop in StAR protein 
(Allen et al. in review). In the current study, peripheral P concentrations again 
dropped 40%, reaching a nadir at 8 hrs following a second infusion of PGF2a. 
Interestingly, StAR exhibited a transient, but non-significant drop in expression that 
did not occur until 16 hrs following PGF2a infusion. The biological significance of 
the asynchrony between peripheral P concentrations and StAR protein expression is 
open to speculation. MMP-2 may be involved. The more rapid increase in MMP-2 
activity (by 1 hr following a second infusion of PGF2a) perturbs the communication 
between the ECM and integrins, and in turn affects the trafficking of cholesterol by 
the cellular cytoskeleton. This is coupled with reports that membrane fluidity may be 
altered by PGF2a (Buhr et al. 1983; Goodsaid-Zalduondo et al. 1982). Therefore, it 
is possible that these changes in membrane fluidity may act in concert with the 
alterations of the ECM, leading to a decreased mobility of both LH and cholesterol 
receptors could account for the drop in P concentrations independent of changes in
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StAR protein. MMP-2 may also act directly on StAR, as MMP-2 is thought to cleave 
StAR from an ~37 kDa active form to an ~30 kDa inactive form upon entering the 
mitochondria (Epstein and Orme-Johnson 1991), which may account for the decrease 
in P synthesis.
The TIMP and MMP family members are mediators of structural remodeling 
events. The balance of MMPs and TIMPs, therefore, determines the rate of turnover 
of the ECM, and it is believed that these mediators may alter the rate of cell adhesion 
and apoptosis in the CL (Stemlicht and Werb 2001). Following a single infusion of 
PGF2a, TIMP-1 and TIMP-2 protein levels plummeted at 1 hr (Towle et al. 2002) 
while MMP-2 activity increased at 4 hrs (Allen et al. in review). In the current study, 
TIMP-1 and TIMP-2 proteins continued to respond acutely following two 1 hr 
infusions of PGF2a, with a drastic decrease in expression at 1 hr, coinciding with an 
elevation of MMP-2 activity. These results are consistent with previous reports in 
which TIMP mRNA levels declined significantly following a luteolytic dose of 
PGF2a in the ovine models (Mclntush et al. 1997). However, other findings indicate 
that both TIMP-1 and TIMP-2 mRNA in the bovine CL increase significantly above 
control levels 8 hrs following a luteolytic dose of PGF2ct (Juengel et al. 1994). The 
dosage of PGF2a, the animal model, and the endpoint measured (mRNA versus 
protein) may account for differences between the current study and that of Juengel et 
al. (1994). In the current study, of note was the significant increase in TIMP-1 protein 
24 hrs following two 1 hr infusions of PGF2a. Because the rise in TIMP-1 parallels 
peripheral P concentrations, and TIMP-1 has been shown to be a promoter of 
steroidogenesis (Boujrad et al. 1995), this could suggest that the CL may upregulate
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TIMP-1 expression as a mechanism to recover from the insult of PGF2a. Further 
study is necessary.
Regarding the gelatinases, while MMP-9 was unchanged, MMP-2 activity 
increased sooner after two infusions of PGF2a than after one (Allen et al. in review; 
Towle et al. 2002). Previously reported data suggests that MMPs are upregulated and 
TIMP mRNA is downregulated, increasing the ratio of MMP:TIMP-1 mRNA and 
protein levels in response to PGF2a, thus creating a microenvironment that favors 
proteolysis (Ricke et al. 2002b). Our finding of an early increase in MMP-2 activity 
following PGF2a infusion may shift the balance between TIMPs and MMPs towards 
proteolysis of the ECM as luteal regression ensues. In fact, low levels of TIMP-2 
stimulate MMP-2 activation by membrane type 1-MMP (Hemandez-Barrantes et al. 
2000). This is due to preferential binding of TIMP-2 preferentially binds MMP-2 at 
the C-terminus (Goldberg et al. 1989), forming a membrane type 1-MMP/MMP- 
2/TIMP-2 triplex, which activates MMP-2 at the cell surface (Strongin et al. 1995). 
The imbalance between TIMPs and MMP-2 throughout two infusions of PGF2a is 
shown in Fig 14.
During PGF2a induced luteolysis in sheep, the interplay among these 
mediators is complex. Our current working model is depicted in Fig 15. Upon 
binding of PGF2a to the large luteal cell, nitric oxide synthase (NOS) is upregulated, 
which generates nitric oxide (NO). In turn, NO stimulates PGF2a production as 
shown in cultured bovine luteal cells (Skarzynski et al. 2003). Thus, there is a 
positive feedback mechanism that links PGF2a and NO in luteal regression (Estevez 
et al. 1999). This is supported by studies that show treatment with a NOS inhibitor
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(N-w-nitro-L-arginine methyl ester) prolongs the lifespan of the bovine CL 
(Jaroszewski and Hansel 2000; Jaroszewski et al. 2003). In addition, NO is produced 
by macrophages (Knight 2000), an important component of the immune system that 
plays a central role in luteolysis (Pate 1994). Furthermore, the NO that is generated 
can react with a superoxide anion (O2’) to yield peroxynitrite (ONOO), which 
inactivates TIMP-1 through catabolism (Frears et al. 1996). As a result of 
peroxynitrite action, TIMP-1 and probably TIMP-2 sharply decline.
PGF2a also increases COX-2 protein expression in the ovine CL (Allen et al. 
in review). Since the peroxynitrite generated from NO also activates COX through 
stimulation of its active site (Mollace et al. 2005), this culminates in the increased 
synthesis of PGF2a, downregulating StAR (Allen et al. in review) and subsequent P 
concentrations. Besides the effects of PGF2a on StAR, P biosynthesis may also be 
affected by perturbations of the cytoskeleton. It is known that the cellular 
cytoskeleton is connected to the ECM via transmembrane integrins (Calderwood et al. 
2000; Choquet et al. 1997). When the ECM is disrupted due to decreased TIMP and 
increased MMP-2 activity, this leads to instability of the cytoskeleton, affecting the 
intracellular trafficking of cholesterol (Niswender et al. 2000).
Conclusions
In conclun, following the second of two 1 hr systemic infusions of PGF2a, 
luteal COX-2 protein remained elevated while COX-1 and StAR protein were 
unchanged. TIMP expression continued to be negatively influenced by PGF2a with 
an apparent inability of TIMP-2 to recover during the early stages of luteolysis.
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Notably, MMP-2 activity was increased sooner from a second dose of PGF2a than 
from a single 1 hr infusion of PGF2a. In addition, studies using this model are 
currently underway to determine the relationship between NO and the above 
mentioned mediators. Thus, future investigations on the fate of these mediators 
following additional infusions of PGF2a are necessary.
Figures
Figure. 5: Experimental design: Bracketed arrows depict the one hour long infusions 
of PGF2a. The triangles indicate the time of luteectomy before (0), and 1, 8, 16, or 
24 hrs following the second infusion of PGF2a.
Figure. 6: TIMP-1: Representative immunoblot and densitometric analysis of TIMP-1 
protein in sheep luteal extracts. The time points are before (0 hr), and at 1, 8, 16, and 
24 hrs from the onset of a second one-hr PGF2a infusion. On the left, molecular 
weight markers are indicated in kilodaltons (kDa). The arrow indicates the relative 
molecular mass of the TIMP-1 protein (—30 kDa), which is consistent with a TIMP-1 
recombinant protein (RP) used as a positive control. For each sheep (n=4), total pixel 
counts for each sample (in duplicate) and for all time points were averaged and 
expressed as a percentage of the total pixel count for each time point over the pixel 
count for the control (time 0) (± SEM). Asterisks denote significance p<0.05.
Figure. 7: TIMP-2: Representative immunoblot and densitometric analysis of TIMP-2 
protein in sheep luteal extracts. The time points are before (0 hr), and at 1, 8, 16, and
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24 hrs from the onset of a second one-hr PGF2a infusion. On the left, molecular 
weight markers are indicated in kilodaltons (kDa). The arrow indicates the relative 
molecular mass of the TIMP-2 protein (-19 kDa), which is consistent with a TIMP-2 
recombinant protein (RP) used as a positive control. For each sheep (n=4) total pixel 
counts for each sample (in duplicate) and for all time points were averaged and 
expressed as a percentage of the total pixel count for each time point over the pixel 
count for the control (time 0) (± SEM). Asterisks denote significance p<0.05.
Figure. 8: Representative zymogram and densitometric analysis of MMP-2 and 
MMP-9 in sheep luteal extracts. The time points are before (0 hr), and at 1, 8, 16, and 
24 hrs from the onset of a second one-hr PGF2a infusion. On the left, molecular 
weight markers are indicated in kilodaltons (kDa). The arrow indicates the relative 
molecular mass of latent MMP-2 (-70 kDa), active MMP-2 (-64 kDa), and active 
MMP-9 (-85 kDa). For each sheep (n=4) total pixel counts for each sample (in 
duplicate) and for all time points were averaged and expressed as a percentage of the 
total pixel count for each time point over the pixel count for the control (time 0) (± 
SEM). Asterisks denote significance p<0.05.
Figure. 9: COX-1: Representative immunoblot and densitometric analysis of COX-1 
protein in sheep luteal extracts. The time points are before (0 hr), and at 1, 8, 16, and 
24 hrs from the onset of a second one-hr PGF2a infusion. The positive control is 
COX-1 recombinant protein (RP). On the left, molecular weight markers are 
indicated in kilodaltons (kDa). The arrow indicates the relative molecular mass of the
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COX-1 protein (-70 lcDa). For each sheep (n=4) total pixel counts for each sample 
(in duplicate) and for all time points were averaged and expressed as a percentage of 
the total pixel count for each time point over the pixel count for the control (time 0) 
(± SEM).
Figure. 10: COX-2: Representative immunoblot and densitometric analysis of COX-2 
protein in sheep luteal extracts. The time points are the untreated time zero prior to 
any infusion (UT), before (0 hr), and at 1, 8, 16, and 24 hrs from the onset of a 
second one-hr PGF2a infusion. COX-2 recombinant protein served as a positive 
control (RP). On the left, molecular weight markers are indicated in kilodaltons 
(kDa). The arrow indicates the relative molecular mass of COX-2 (-72 kDa). For 
each sheep (n=4) total pixel counts for each sample (in duplicate) and for all time 
points were averaged and expressed as a percentage of the total pixel count for each 
time point over the pixel count for the control (time 0) (± SEM).
Figure. 11: StAR: Representative immunoblot and densitometric analysis of StAR 
protein in sheep luteal extracts. The time points are before (0 hr), and at 1, 8, 16, and 
24 hrs from the onset of a second one-hr PGF2a infusion. The positive control is 
untreated, mid-cycle bovine luteal tissue (BLT). On the left, molecular weight 
markers are indicated. The arrow indicates the relative molecular mass of the (-30 
kDa) StAR protein. For each sheep (n=4) total pixel counts for each sample (in 
duplicate) and for all time points were averaged and expressed as a percentage of the
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total pixel count for each time point over the pixel count for the control (time 0) (± 
SEM).
Figure. 12: Mean concentration of progesterone in mid-cycle ewes (n=20)
administered two one-hour infusions of PGF2a (20 pg/min/hr). Open triangles 
indicate times of luteectomies (n=4), performed at specific intervals (0, +1, +8, +16, 
+24 hours) relative to the second infusion of PGF2a.
Figure. 13: COX-2 protein expression after two infusions of PGF2a. Data are 
expressed as a percent of controls (0 hr time point, untreated) versus time in hours 
after the onset of PGF2a infusion. Arrow brackets indicate infusions of PGF2a.
Figure. 14: Ratio of TIMP and MMP expression after two infusions of PGF2a. Data 
are expressed as a ratio of MMP-2:TIMP-1 and MMP-2:TIMP-2, based on percent of 
controls (0 hr time point, untreated) versus time in hours after the onset of PGF2a 
infusion. Arrow brackets indicate infusions of PGF2a
Figure. 15: Our working cell model: 1) PGF2a binds a FP receptor and stimulates 
NOS and NO production. 2) Peroxynitrite catabolizes TIMP-1 and TIMP-2. 3) 
Imbalance of MMP to TIMP leads to ECM disruption and perturbations in 
steroidogenesis. 4) Delayed induction of COX-2 facilitates an auto-amplification 
feedback loop of PGF2a, possibly initiating cell death machinery.
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Fig. 1
Experimental Design
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Fig. 9 Cumulative COX-2 Protein Levels Following Two Infusions of PGF2a
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0.02% Sodium Azide 
10mMEDTA\
1% Triton X-100
pH 7.4, prior to adding Triton X-100 
Bring to volume with cold ddHiO
ALL steps are performed on ice, or @ 4°C
1. Add protease inhibitors to extraction buffer immediately before use:
a. lpg/ml AEBSF
b. lpg/ml Pepstatin A
c. lpg/ml Aprotinin
2. Remove tissue from freezer, weigh, and thaw on ice in Petri dish cover.
3. Add extraction buffer in a ratio of 8ml for every Ig of tissue weight. Record 
weight and volume of extraction buffer used.
4. Mince with scalpel. Once tissue is minced transfer to 15 ml conical tube.
5. Homogenize tissue @ speed 8 for 30 seconds on ice.
6. Rinse polytron probe with ddHiO between samples. If necessary remove any 
tissue debris from polytron probe with tweezers.
7. Repeat homogenization (steps 5-6)
8. Separate into two separate tubes. One tube for COX samples and the other for 
StAR samples.
9. Sonicate samples that contain membrane bound molecules of interest:
a. Transfer 0.5ml of sample into 1.0ml eppindorf tube
b. Settings: timer = hold, continuous; output = 3
c. On ice sonicate sample twice for 10 seconds each, rinse probe between 
samples with extraction buffer
10. Centrifuge @ 4°C, 800 x g for 10 minutes
11. Transfer supernatant into new tubes (discard fat layer and pellet) and 
centrifuge @ 4°C, 10,000 x g for 10 minutes. Repeat until samples are clear.
12. Transfer supernatant into new tubes and store @ -80°C.
96
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Appendix B. Protein Extraction Method (B)
Solutions:
Extraction Buffer (pH 7.6) CAB+ Assay Buffer (lOx stock; pH 7.6)
116.9gNaCl 116.9g NaCl
2.4g HEPES 60.6g Tris
0.2g Sodium Azide 1.5g CaCk
Bring to 1L with ddH20  2.0g Sodium Azide
Bring to 1L with ddH20; pH @ 4°C
DAY 1
Perform all procedures on ice:
1. Thaw luteal tissue on ice. Blot briefly, weigh, and record mass.
2. Mince with scalpel on Petri dish cover over ice. Add extraction buffer in a 
ratio of 1.0ml buffer per 0.2g of tissue weight. Record volume of buffer 
used
3. Put minced tissue/buffer in centrifuge tubes. Cap tightly and parafilm.
4. Tape tubes onto Clay Adams Nutator Mixer (Beckton Dickenson; Sparks, 
MD). Nutate in cold room (4°C) overnight (23-24 hrs).
DAY 2
Perform all procedures on ice or in 4°C centrifuge:
1. Centrifuge extract for 15 minutes @ -3,000 x g to pellet tissue
2. Pipet supernatant into 1.5ml microcentrifuge tubes and centrifuge for 30 
minutes @15,000 x g to remove particulate matter.
3. Remove supernatant to new microcentrifuge tubes and repeat 
centrifugation until supernatant is clear (not flocculent).
4. Pipet clear supernatant into Amicon Ultra (Amicon; Beverly, MA) 
ultrafiltration and concentrator device (max volume = 4ml/ concentrator)
5. Centrifuge in a fixed-angle centrifuge for - lh r  @ 3,200 x g. Continue to 
centrifuge until volume of retentate equals -200 pi.
6. Wash/dialyze twice with 2 volumes of IX CAB+ assay buffer (dilute 
stock 1:9) and continue to centrifuge.
7. Determine 1/4th of original buffer used (4X concentration). Centrifuge to 
this volume or more. If necessary bring final volume up using CAB+.
8. Pipet retentate into sterile micofuge tubes and store @ 4°C in aliquots.
9. Replenish sodium azide (0.02%) in stored samples every 1-2 months.
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Appendix C. Bradford Protein Determination
Phosphate Buffered Saline (PBS):
27.4ml 0.25 Na2HP04 
13.7ml 0.25 NaH2P04 
8.1g NaCl
Bring to volume to 1L with ddH20, pH 7.4
1. Set up standard curve (in duplicate) in check tube size
Tube # BSA PBS
1-2 0 800pl
3-4 4pl (2pg) 796pl
5-6 8 pl (4pg) 792pl
7-8 12pl (6pg) 788pl
9-10 16pl (8pg) 784pl
11-12 20pl (10pg) 780pl
2. Set up diluted (1:10) samples (induplicate) in check tubes:
Tube # BSA PBS
13-14 2pl 800pl
15-16 4pl (2pg) 796pl
17-18 6pl (4pg) 792pl
19-20.. 8pl (6pg) 788pl
* continue dilutions as needed
* repeat for each sample
3. Add 200pl of BioRad Bradford Assay Reagent, and vortex.
4. Read absorbance at 595nm and record readings.
5. Graph standard curve with pg BSA on X-axis and absorbance on Y-axis.
6. Using the regression line equation, calculate the concentration of protein 
the sample (pg/pl).
7. If absorbances fall out of range repeat using necessary dilutions 
concentrations.
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Appendix D. Zymography and Immunoblot Solutions
Solutions:
Ammonium Persulfate Solution (APS; lOOmg/ml) 
20mg ammonium persulfate 
200ml ddH20
4mM APMA Solution





Stacking Gel (4% acrylamide)
6.36ml ddH20  
2.52ml 0.5M Tris (pH 6.8)
1.0ml 40% acrylamide 
100ml 10% SDS
50pl ammonium persulfate (lOOmg/ml) 
lOpI TEMED
1.5M Tris (pH 8.8)
18.17g Tris 
100ml ddH20
0.5M Tris (pH 6.8)
6.06g Tris 
100ml ddH20
0.25M Tris (pH 6.8)
3.03g Tris 
100ml ddH20
Sample Buffer (10ml) 




Separation Gel (10% acrylamide) 
7.5mg gelatin 
7.275ml ddH20  
3.75ml 1.5M Tris (pH 8.8) 
3.75ml 40% acrylamide 
150pl 10% SDS 
proteins)






Bring to 1L with ddH20
Coomassie Stain
2.5g Brilliant Blue R-250 
50.0ml Acetic Acid 
150.0ml Isopropyl Alcohol 
300.0ml ddH2Q
Separation Gel (12% acrylamide)
No gelatin for Western blots
6.525ml ddH20
3.75ml 1.5M Tris (pH 8.8)
4.5ml 40% acrylamide
(4.688ml 40% acrylamide for COX





970.0mg CaCl2-2H20  
200.0mg Sodium Azide 
Bring to 1L with ddH20
2.5% Triton X-100 Solution
5.0ml Triton X-100 
195.0ml ddH20
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Appendix E. Immunoblot (Western) Solutions and Protocol
Solutions:
TBST Buffer Blotting Buffer
1.2g Tris 800ml ddFfeO
8.8g NaCl 200ml Methanol
0.5ml Twenn 20 15.03g Glycine
Bring up to 1L with ddfkO 3.15g Tris
5% Milk




1. Cast gels using zymography recipes:
a. Separation gel: 12% acrylamide for TIMPs and COXs, 12.5% 
forStAR
b. Stacking gel: 4% acrylamide
2. Use BioRad Precision Plus Protein Standards for molecular weight 
markers.
3. Load controls and samples- electrophoresis is the same as zymography
Part 2. Preparation for blotting.
1. Cut four pieces of filter paper and prepare four pieces of blotting sponge.
2. Cut nitrocellulose membranes to fit atop of gels accordingly.
3. When gels are almost done running, make blotting buffer- add methanol 
last. Let blotting paper/sponges and nitrocellulose membranes equilibrate 
in blotting buffer for several minutes.
4. When electrophoresis is complete, cut off stacking gel, and equilibrate in 
blotting buffer for several minutes. Repeat for 2nd gel.
5. Notch the top left comer of the nitrocellulose to maintain orientation.
Part 3. Electroblotting.
1. On the black side of the plastic sandwich place in order: one white Teflon 
blotting sponge, and filter paper.
2. Place gel on top of filter paper and cover with nitrocellulose membrane 
maintaining the correct orientation.
3. Finish assembling sandwich by repeating the order filter paper > blotting 
sponge.
4. Insert sandwich into electrode cassette with the black part of the sandwich 
facing the black portion of the electrode cassette. Place cassette into tank 
with blotting buffer.
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5. When both sandwiches are assembled in the tank, add a small stir bar, and 
ice pack into the open area. Fill the tank with any necessary additional 
blotting buffer.
6. Place tank assembly into a basin filled with ice, on top of a stir plate.
7. Place electrode cover onto tank and set power source to 200mA constant 
for 2 hours.
Part 4. Blocking.
1. Before blotting is complete, make blocking buffer (5% milk).
2. Once blotting is complete, remove nitrocellulose membranes and place 
them into ~50ml of blocking buffer on shaker for 1-2 hours.
Part 5. Adding the primary antibody.
1. Before blocking is complete, remove an aliquot of the primary antibody 
from the freezer, allow to thaw, and reconstitute in appropriate volume of 
blocking buffer.
2. When blocking is complete, discard milk.
3. Slowly add antibody onto the nitrocellulose membrane (usually ~5ml/per
gel).
4. Cut two pieces of parafilm just slightly larger than the membrane and 
place on top, making sure to avoid air bubbles (ensures antibody contact 
with membrane).
5. Let incubate overnight, 12-16 hours in 4°C cold room on slow shaker.
Part 6. Washing membranes.
1. Remove the primary antibody and return the refrigerator or freezer for 
storage.
2. Rinse quickly with TBST to remove residual primary antibody, then 
replace TBST and place on shaker for 10 minutes. Repeat 3-4 times.
3. During the last rinse prepare secondary antibody in blocking buffer.
Part 7. Adding the secondary antibody.
1. Make 50ml of blocking buffer, add 5 pi of secondary antibody.
2. Remove TBST from the membranes and add 25ml of secondary antibody 
per membrane.
3. Cover and put on a low shake for 1-2 hours.
Part 8. Second set of washes.
1. After incubation, discard secondary antibody.
2. Quickly rinse with TBST, and repeat 3-4 times.
3. Before beginning the final series of washes turn on the film processor in 
the dark room.
Part 9. Chemiluminescent detection.
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1. During the last 5 minutes of the last wash, make up Super Signal 
chemilumiscent reagent with the lights off. (Pierce kit; 5ml of each 
solution)
2. When washing is complete, discard buffer and add 5ml of Super Signal to 
each membrane.
3. Let incubate for 5 minutes
Part 10. Prepare membranes for documentation.
1. Place a piece of saran wrap -12 inches long ~8inches wide on a flat clean 
surface.
2. Using tweezers, shake excess Super Signal off onto kimwipe and place the 
membranes in reverse orientation onto the surface.
3. Place a piece of filter paper on top of the membranes then carefully wrap 
the saran wrap around the filter paper.
4. Turn over (should be in correct orientation now) and place into the film 
cassette and tape to prevent moving.
5. Bring film cassette into darkroom and expose film on membranes (time 
depends on protein presence) and process film.
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Appendix F. Zymography Protocol:
DAY 1
1. Heat water bath (500ml beaker on hot plate) to ~90°C.
2. Make ammonium persulfate solution (APS) in 1.5ml microcentrifuge tube.
3. Weigh gelatin and place in a 50ml centrifuge tube.
4. Prepare gel solution:
a. Add ddH20 to tube, followed by 1.5M Tris (pH 8.8), 40% 
acrylamide (wear gloves), and SDS.
b. Heat contents in hot water bath (30sec dips) until gelatin dissolves.
c. Let cool to -room temperature
5. Set up gel apparatus:
a. Rinse and dry all components.
b. Place rubber gaskets onto tower (as needed) and cover with
parafilm.
c. Assemble plates with one large plate, one small, and two 1mm 
spacers between them.
d. Tighten the knobs of the assembly making sure all plates and 
spacers are even.
e. Snap plates into tower with knobs facing away.
f. To check for leaks, add ddHzO between the plates and monitor 
fluid levels. If levels drop reassemble plates and repeat d-f.
g. Make sure plates are relatively dry before continuing.
6. Casting the separation gel:
a. Add TEMED and APS to the gel solution and swirl to mix
b. With a Pasteur pipette, quickly load the gel solution between the 
two plates. Fill to the notch on the snap tower.
c. With a clean Pasteur pipette, add ddHzO on top of the gel solution 
slowly and evenly.
d. Allow gel to polymerize (20-40 minutes).
7. Casting the stacking gel:
a. When separation gel is almost polymerized, add all ingredients for 
the stacking gel solution in order, except TEMED and APS.
b. Dump off water on top of separation gel once polymerized and dry 
area with Whatman filter paper.
c. Add TEMED and APS to the solutions and swirl to mix.
d. Load the stacking gel solution on top of the separation gel.
e. Immediately insert a 1mm thick 10 well comb into the center of the 
gel.
f. Allow to polymerize (20-40 minutes)
8. Preparing standards and samples:
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a. While the stacking gel is polymerizing, make up loading samples 
in 0.5ml microcentrifuge tibes.
b. Use an equal volume of sample to loading buffer (1:1), unless 
otherwise indicated.
9. Loading samples:
a. When stacking gels are polymerized, carefully remove combs.
b. Remove the gels/glass assembly from tower and insert into 
electrode tower.
c. Place the new assembly into gel tank and add ~800ml of lx 
electrode buffer to the center area between gels, making sure to 
gently rinse the wells of the gel.
d. Begin loading samples (gel loading tips):
1. Max volume 40-50pl.
2. Avoid using 1st and last lanes, use same volume of loading 
buffer as a blank to allow the gel to run consistently.
3. Record samples contents for each lane of each gel.
10. Running the gels:
a. Once gels are loaded, attach electrode cover in proper orientation.
b. Plug electrode cover into power source and set volts to 200.
c. Rim until dye reaches the bottom of the gel.
d. Prepare the Triton X-100 solution during the last 15 minutes of 
running.
11. Triton washes:
a. When the gel is finished running, remove gels from the apparatus 
and place them into 150mm Petri dishes and label.
b. Cover gels with ~100ml Triton solution and place on shaker 
vigorously for 15 minutes.
c. Drain off Triton and repeat step b-c.
d. When 2nd wash is complete, rinse gels with ddfLO
12. Fill each dish with ~ 150ml of substrate buffer.
13. Place on shaker in 37°C incubator and shake gently overnight.
DAY 2
1. Staining the gels:
a. Remove from incubator and pour off substrate buffer.
b. Add 50ml of coomassie solution to each dish
c. Shake gently at room temperature for 30 minutes.
2. Destain gels:
a. Aspirate off coomassie stain. Rinse gels several times with ddFLO.
b. Shake gels in ddfUO at room temperature, changing water 
periodically until zones of clearing are visible (up to 3 days).
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c. When gels are of satisfactory intensity, take a picture and store gels 
in sealed plastic sleaves.
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